Document:

EX-10.10

 Exhibit 10.10 

CONFIDENTIAL TREATMENT REQUESTED 
 [*] = Certain
confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the
Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 CONFIDENTIAL 

AMENDED AND RESTATED 

DEVELOPMENT AND LICENSE AGREEMENT 

BETWEEN 
 COLUCID
PHARMACEUTICALS, INC. 
 AND 

ELI LILLY AND COMPANY 

EFFECTIVE AS OF FEBRUARY 10, 2015 

 AMENDED AND RESTATED 

DEVELOPMENT AND LICENSE AGREEMENT 

THIS AMENDED AND RESTATED DEVELOPMENT AND
LICENSE AGREEMENT (the “Agreement”), is entered into as of February 10, 2015 (the “Restatement Effective Date”), by and between
COLUCID PHARMACEUTICALS, INC. (“CoLucid”), a corporation organized and existing under the laws of the State of Delaware, having its principal place of
business at 902 North Capitol Avenue, Suite 302, Indianapolis, Indiana 46204, and ELI LILLY AND COMPANY (“Lilly”), a corporation organized and
existing under the laws of the State of Indiana, having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285. CoLucid and Lilly are sometimes referred to herein individually as a “Party” and
collectively as “Parties.” The Parties agree as follows: 
 BACKGROUND 

Lilly has certain intellectual property rights relating to its compound LY573144. CoLucid is interested in further developing
and commercializing LY573144. The Parties entered into a Development and License Agreement, dated December 16, 2005 (the “Original Agreement”), pursuant to which Lilly granted CoLucid a license to further develop and
commercialize, on a worldwide basis, pharmaceutical products containing LY573144. 
 The Original Agreement was
amended (or certain matters confirmed) pursuant to (i) a letter dated December 16, 2005; (ii) a letter dated March 27, 2008; (iii) a letter dated June 6, 2008; (iv) an amendment dated as of May 29, 2014; and
(v) a letter dated January 6, 2015 (collectively, the “Prior Amendments”). The Parties desire to further amend the Original Agreement and to restate the Original Agreement in its entirety as set forth in this
Agreement, after which this Agreement shall represent the complete understanding of the Parties with respect to the subject matter hereof and supersedes and replaces the Original Agreement and Prior Amendments. 

NOW, THEREFORE, in consideration of the above premises and the mutual covenants and agreements set forth
below, the Parties hereto agree as follows. 
 ARTICLE 1 

DEFINITIONS 
 As used in
this Agreement, the following words and phrases shall have the following meanings: 
 “Adverse Event” means any untoward
medical occurrence in a patient or clinical investigation subject administered a medicinal product that may have, but does not necessarily have to have a causal relationship with the medicinal product, including as designated under 21 C.F.R. 312.32
and any other Applicable Laws. 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

1 

 “Affiliate” means, with respect to a Party, any Person directly or indirectly
controlling, controlled by, or under common control with, such Party. For purposes of this Agreement, the term “controlled” (including the terms “controlled by” and “under common control with”) as used in this context,
means the direct or indirect ability or power to direct or cause the direction of management policies of a Person or otherwise direct the affairs of such Person, whether through ownership of equity, voting securities, beneficial interest, by
contract or otherwise. 
 “Applicable Laws” means all applicable laws, ordinances, rules and regulations of any kind
whatsoever of any governmental (including international, foreign, federal, state and local) or regulatory authority, including, without limitation, all laws, ordinances, rules and regulations promulgated by the FDA or its counterparts in foreign
jurisdictions. 
 “Application for Marketing Authorization” means, with respect to Product, (i) in the United
States, a New Drug Application filed with the FDA pursuant to 21 U.S.C. Section 357 and 21 C.F.R. Section 314 or any successor regulatory scheme (“NDA”), and (ii) in any country other than
the United States, an application or set of applications for marketing approval comparable to an NDA and necessary to make and sell Product commercially in such country. 

“Calendar Quarter” means the three (3) month period ending on March 31, June 30, September 30
or December 31. The initial Calendar Quarter will be deemed to begin on the Original Effective Date and end on the expiration of that Calendar Quarter in which it falls. 

“Change of Control” means, with regard to a Party, any of the following events: the acquisition by any Person, other than a
Person controlling such Party as of the Original Effective Date, of “beneficial ownership” (as defined in Rule 13d-3 under the United States Securities Exchange Act of 1934, as amended), directly or indirectly, of more than fifty percent
(50%) of the shares of such Party’s stock by way of merger or sale of stock (excluding any bona fide financing transactions) or the sale or other disposition of all or substantially all of the assets of such Party to a Third Person. 

 “Clinical Trial(s)” means Phase I Clinical Trials, Phase II Clinical Trials or Phase III Clinical Trials, as
applicable. 
 “Closing Date” means the date of the closing of the Next Financing, so long as such closing date occurs
within sixty (60) days after the Original Effective Date (or such later date as the Parties may agree). 
 “CoLucid
Technology” means any inventions, ideas, conceptions or reductions-to-practice, patentable or not, information, works and data that are (i) generated, identified, discovered, created or made, in
whole or in part, by CoLucid, its Affiliates, its employees or a Third Person on behalf of CoLucid, (ii) Controlled by CoLucid or its Affiliates, and (iii) necessary to manufacture, use, research, develop, sell or seek Regulatory Approval,
including, without limitation, manufacturing processes, formulations, modes of delivery and methods of use, toxicology studies, Clinical Trial 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

2 

 
information and data, and post-registration Clinical Trial information and data; in each case relating to the Compound or the Product. 

“Combination Product” means any product comprised of a combination of a Product and other product(s) or product component(s)
where: (i) the manufacture, importation, use or sale or other disposition of the other product(s) or product component(s) by itself by or on behalf of CoLucid or another Permitted Seller does not constitute an infringement of a Valid Claim;
(ii) the other product(s) or product component(s) can be sold separately by CoLucid or another Permitted Seller; and (iii) the other product(s) or product component(s) enhances the market price of the Product sold by CoLucid or another
Permitted Seller. 
 “Compound” means 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridyl]-benzamide,
which is designated as LY573144, and/or any of its pharmaceutically acceptable salts, solvates, or polymorphs. 
 “Compound
Supply” shall have the meaning set forth in Section 5.1. 
 “Confidential Information” means information
received (whether disclosed in writing, electronically, orally or by observation) by one Party (the “Receiving Party”) from the other Party (the “Disclosing Party”) that the
Disclosing Party reasonably considers proprietary and confidential unless in each case such information, as shown by competent evidence: 

(a) was known to the Receiving Party or to the public prior to the Disclosing Party’s disclosure, as demonstrated by
contemporaneous written records; 
 (b) became known to the public, after the Disclosing Party’s disclosure hereunder, other than
through a breach of the confidentiality provisions of this Agreement by the Receiving Party or any Person to whom such Receiving Party disclosed such information; 

(c) was subsequently disclosed to the Receiving Party by a Person having a legal right to disclose, without any restrictions, such
information or data; or 
 (d) was developed by the Receiving Party independent of the Disclosing Party’s Confidential
Information; 
 provided, however, that the Licensed Patents, the Lilly Know-How and any other information that pertains to Compound or any Product
disclosed to CoLucid by Lilly hereunder shall be deemed the Confidential Information of CoLucid as well as Lilly and subject to the confidentiality provisions hereof during the term of this Agreement. 

“Control” means the possession of the ability to grant a license without violating the terms of any agreement or other
arrangement with any Third Person. 
 “Damages” means any and all costs, losses, claims, demands for payment,
government enforcement actions, liabilities, fines, penalties, expenses, court costs and 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

3 

 
reasonable fees and disbursements of counsel, consultants and expert witnesses incurred by a Party hereto or its Affiliates (including any court-imposed interest in connection therewith).

 “Data Exclusivity Period” means the period during which the FDA (or, in countries other than the United States, an
equivalent regulatory agency) prohibits reference, without the consent of the owner of an Application for Marketing Authorization or Regulatory Approval package, to the clinical and other data that is contained in such Application for Marketing
Approval or Regulatory Approval package, and that is not published or publicly available outside of such Application for Marketing Authorization or Regulatory Approval package. 

“Development Plan” means a plan prepared by CoLucid for developing Product in the Territory, up to and including filing of
the Application for Marketing Authorization for the Product, including all Clinical Trials required to confirm the profile of Product, including but not limited to, Clinical Trials required to confirm the clinical efficacy, tolerability and dosing
regimen of Product. The initial Development Plan is attached as Exhibit C; provided, however, that CoLucid shall be entitled to amend, alter or change such Development Plan in its sole discretion, subject to its
obligations hereunder. 
 “Diligence” means use of reasonable commercial efforts, consistent with normal business
practices within the pharmaceutical industry, taking into account efficacy, the competitiveness of alternative products in the marketplace, the availability of a partner for commercialization of a Product, the degree of intellectual property
protection available for a Product, the likelihood of Regulatory Approval, the profitability of a Product, the potential impact of the prevailing conditions (such as pricing) in one market on one or more other markets, alternative products and other
relevant factors, and in any event not less than the use of efforts comparable with those used by CoLucid for similar products at a comparable stage in development and of a comparable commercial and development potential in light of such factors,
with the objective of launching a Product worldwide as soon as practicable. 
 “FDA” means the United States Food
and Drug Administration, or any successor federal agency having responsibility over Regulatory Approval. “FDA” shall also be deemed to include the applicable governmental or regulatory authority having jurisdiction over the Product in any
particular country or region in the Territory (for example, the European Medicines Evaluation Agency for the European Union). 

“Field” means all human health uses.  

“First Commercial Sale” means the first arms-length sale of Product in a country by CoLucid or a Permitted Seller to a Third
Person following Regulatory Approval in that country. 
 “Force Majeure” shall have the meaning set forth in Section
12.3. 
 “GAAP” means U.S. Generally Accepted Accounting Principles, consistently applied. 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

4 

 “Licensed Patents” means those United States and foreign patents and patent
applications (including provisional applications) listed in Exhibit A to the extent they cover making, using or selling Compound, including, without limitation: 

(a) all divisions and continuations of these applications, all patents issuing from such applications, divisions and
continuations, and any reissues, reexaminations and extensions of all such patents; and 
 (b) any
continuations-in-part, any divisions and continuations of these continuations-in-part, any patents issuing from such continuations-in-part, divisions and continuations, and any reissues, reexaminations and extensions of all such patents, in each
case to the extent that they contain one or more claims directed to the invention or inventions disclosed in the patent applications listed in Exhibit A.  

“Lilly Know-How” means any and all know-how, trade secrets, inventions, technology, information, data, ideas, specifications,
formulas or formulations, procedures, processes, plans, designs, instructions, studies, methods, or any similar items, and any related documentation, records, or materials, relating to Compound (including information relating to the previous
generation compound known as LY334370, but only to the extent relevant to development of Compound), that are owned or Controlled by Lilly as of the Original Effective Date and necessary or relevant to manufacture, use, research, develop, or sell or
seek Regulatory Approval for the Product, including any: preclinical or clinical development data or information; biological, chemical, pharmacological, toxicological, or pharmaceutical data or information; manufacturing methods, manufacturing and
quality control data or information; formulation analyses; market research specific to Product; or any similar items. Lilly Know-How does not include the Licensed Patents. 

“Major Market(s)” means Japan, France, Germany, Italy, Spain, the United Kingdom, and the United States. 

“NDA” has the meaning set forth under definition of “Application for Marketing Authorization”. 

“Net Sales” means the gross amount invoiced for sale of Products by a Permitted Seller less the following items, consistent
with GAAP:  
 (a) trade, quantity and cash discounts actually allowed; 

(b) commissions, discounts, refunds, rebates, charge backs, retroactive price adjustments, and any other allowances paid to
third parties that effectively reduce net selling price; 
 (c) actual Product returns and allowances; 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

5 

 (d) any taxes or duties imposed on the production, sale, delivery or use of
Products including, but not limited to, sales, use, excise or value added taxes, other than income taxes; and 
 (e) any
other expenses directly related to the sale of Products that are allowed by GAAP, provided that such expenses are reasonable and taken in good faith. 

For Products which are sold as Combination Products, the Net Sales for such Combination Products shall be adjusted by multiplying the actual
Net Sales by the fraction A/(A+B) where A is the invoice price of the Product, if sold separately, and B is the invoice price of the other product or product component if sold separately. If the other product or product component is not sold
separately, then the actual Net Sales shall be adjusted by multiplying the actual Net Sales by the fraction A/C where A is the invoice price of the Product if sold separately and C is the invoice price of the Combination Product. If neither of the
foregoing applies, then the Parties shall determine the Net Sales of the Combination Product in good faith. 
 Net Sales amounts shall be
determined from the books and records of the Permitted Seller and maintained in accordance with GAAP, consistently applied. Further, in determining such amounts, CoLucid will use CoLucid’s then current standard procedures and methodology,
including CoLucid’s then current standard exchange rate methodology for the translation of foreign currency sales into U.S. Dollars or, in the case of other Permitted Sellers, such similar methodology, consistently applied. 

“Next Financing” means CoLucid’s next sale of its preferred stock after the Original Effective Date, with aggregate
proceeds to CoLucid equal to or exceeding $5,000,000 (including any proceeds attributable to the conversion of unpaid principal amounts and unpaid accrued interest on any outstanding convertible promissory notes issued by CoLucid), to venture
capital, institutional or private investors, in a single transaction, or in a series of related transactions. 
 “Original
Agreement” has the meaning set forth in the first paragraph under “BACKGROUND” above.  
 “Original
Effective Date” means December 16, 2005. 
 “Permitted Seller” means CoLucid and its Affiliates and
any permitted assignee, licensee or sublicensee having the right to sell Product hereunder.  
 “Person” means a
natural person, a corporation, a partnership, a trust, a joint venture, a limited liability company, any governmental authority, or any other entity or organization.  

“Phase I Clinical Trials” means human clinical trials conducted to establish an initial safety profile and pharmacodynamics
of Product in the particular indication tested.  

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

6 

 “Phase II Clinical Trials” means human clinical trials conducted to achieve a
level of efficacy and safety of Product as well as a preliminary dosage in the particular indication tested.  
 “Phase III
Clinical Trials” means human clinical trials conducted to establish efficacy of Product and meet requirements to file Applications for Marketing Authorization for Product with health regulatory authorities in the particular indication
tested. 
 “Prior Amendments” has the meaning set forth in the second paragraph under “BACKGROUND” above.
 
 “Product” means any final form human pharmaceutical composition or preparation, in any dosage strength or size,
for any mode of administration, containing Compound. Subject to the foregoing, product shall be deemed to include all expansions, improvements and modifications thereon made by or on behalf of CoLucid or an Affiliate or otherwise owned or controlled
by CoLucid or an Affiliate. 
 “Regulatory Approval” means approval of an Application for Marketing Authorization and
satisfaction of any related applicable FDA registration and notification requirements (if any).  
 “Regulatory
Documents” shall have the meaning as set forth in Section 11.3(e). 
 “Restatement Effective
Date” shall have the meaning set forth in the first paragraph hereof. 
 “Royalty Term” means, with respect
to each country in which the Product is sold, on a Product by Product basis, that time period beginning on the First Commercial Sale of Product in such country and expiring, on a country-by-country basis, on the following date: 

(a) the later of the tenth anniversary of the date of First Commercial Sale of Product in such country or the expiration in
such country of the last-to-expire Licensed Patent with a Valid Claim; or 
 (b) if there is a Data Exclusivity Period in
effect in such country for Product after the expiration of the applicable time period in (a) which provides effective market exclusivity for the Product, above, the expiration of such Data Exclusivity Period in such country. 

“Territory” means all countries of the world. 

“Third Person” means Persons other than the Parties or Affiliates thereof. 

“Valid Claim” means a claim of an issued and unexpired patent included within the Licensed Patents in a country which:
(i) but for this Agreement, would be infringed by the manufacture, importation, use or sale or other disposition of Product by or on 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

7 

 
behalf of CoLucid or another Permitted Seller, (ii) has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction,
unappealable or unappealed within the time allowed for appeal, and (iii) has not been abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. 

ARTICLE 2 
 GRANT OF
LICENSE 
 2.1 License. Subject to the terms and conditions set forth herein, during the term of this Agreement, Lilly grants
CoLucid an exclusive (except as to Lilly for internal research purposes as set forth in Section 2.2 below) license (with the right to sublicense in accordance with Section 2.4) under Lilly Know-How and Licensed Patents to make, have made,
use, sell, offer for sale, and import Compound and Product in the Field in the Territory, which license shall be effective as of the Closing Date.  

2.2 Reservation of Rights. Notwithstanding the license granted to CoLucid under Section 2.1, Lilly reserves the right under the
license to conduct research on Compound and Product for internal research purposes only. 
 2.3 [Intentionally Omitted.] 

2.4 Sublicensing Rights - CoLucid Sublicenses. CoLucid may sublicense the rights granted hereunder to any of its Affiliates or any
Third Person, provided, however, that CoLucid shall notify Lilly thirty (30) days in advance of granting any sublicense and will discuss in good faith any concerns Lilly may have with such sublicense. CoLucid will remain liable for royalty
payments as a result of Net Sales made by a Permitted Seller pursuant to a sublicense and for any milestone or other payments permitted pursuant to this Section 2.4. Each sublicense granted by CoLucid under this Agreement will contain
provisions that obligate sublicensees to CoLucid to at least the same extent that CoLucid is obligated to Lilly under this Agreement. Additionally, promptly after execution, CoLucid shall provide Lilly with a copy of all sublicense agreement(s). 

 ARTICLE 3 

CONSIDERATION 
 3.1
Payments from CoLucid to Lilly.  
 (a) Issuance of Common Stock. On the
Closing Date and subject to the terms and conditions hereof, CoLucid shall issue to Lilly a number of shares (the “Initial Shares”) of CoLucid’s Common Stock (the “Common Stock”) such that
immediately after the initial closing of the Next Financing, Lilly will own 10% of the Post-Financing Shares of Common Stock (as hereinafter defined) outstanding immediately after the initial closing of the Next Financing. In the event the investors
in the Next Financing purchase additional shares of CoLucid’s 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

8 

 
preferred stock pursuant to the transaction agreements entered into for the Next Financing in any subsequent closing (each a “Subsequent Closing”),
CoLucid shall issue to Lilly such additional shares of Common Stock (the “Supplemental Shares”; together with the Initial Shares, the “Shares”) immediately after a Subsequent Closing such that Lilly
will own 10% of the Post-Financing Shares of Common Stock outstanding immediately after each Subsequent Closing of the Next Financing. “Post-Financing Shares of Common Stock” means the shares of CoLucid’s Common Stock
(assuming conversion of outstanding shares of CoLucid’s preferred stock into common stock at the then applicable conversion rate): (i) issued prior to the date hereof; plus (ii) issued or issuable to Sention, Inc.
(“Sention”) in connection with the Next Financing as provided in the Asset Purchase Agreement dated as of the date hereof between CoLucid and Sention as of the applicable closing date of the Next Financing; plus
(iii) issued in the Next Financing (up to a maximum aggregate Next Financing amount of $16.5 million); plus (iv) issued or reserved for issuance pursuant to the exercise of stock options which have or may be granted under CoLucid’s
stock option plan as of the Closing Date; plus (v) issued or issuable to Lilly pursuant to this Agreement as of the applicable closing date of the Next Financing.  

(b) CoLucid’s Payment Upon the Closing Date. On the Closing Date, CoLucid will pay to Lilly the non-creditable,
non-refundable sum of One Million Dollars ($1,000,000.00) by Federal Reserve electronic wire transfer in immediately available funds to an account designated by Lilly.  

(c) Milestone Payments from CoLucid to Lilly. Within thirty (30) days of CoLucid or its Permitted Sellers achieving
a milestone event listed below with respect to the Product, CoLucid will notify Lilly in writing thereof and pay the below-specified non-creditable and non-refundable fees to Lilly by Federal Reserve electronic wire transfer in immediately available
funds to an account designated by Lilly. 
  

			
	Milestone Event	  	Payment
		
	Filing of First NDA in US	  	Three Million Dollars ($3,000,000)
		
	Filing of First NDA in EU in a Major Market	  	One Million Five Hundred Thousand Dollars ($1,500,000)
		
	Filing of First NDA in Japan	  	One Million Five Hundred Thousand Dollars ($1,500,000)
		
	First Regulatory Approval in US	  	Eleven Million Dollars ($11,000,000)
		
	First Regulatory Approval in EU in a Major Market	  	Two Million Five Hundred Thousand Dollars ($2,500,000)

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

9 

			
	Milestone Event	  	Payment
		
	First Regulatory Approval in Japan	  	Two Million Five Hundred Thousand Dollars ($2,500,000)
		
	First fiscal year of CoLucid in which aggregate Net Sales exceed [*]	  	Ten Million Dollars ($10,000,000)
		
	Approval of each subsequent indication (may be paid more than one time for the Compound)	  	One Million Dollars ($1,000,000) per indication per market (US, EU in Major Market, Japan)

 For the avoidance of doubt, CoLucid shall not be required to pay any milestone more than one time for the
Compound, except as stated above. 
 If any milestone event is achieved with respect to Compound and at such time any one or more of the
milestone events previously listed for the country in which the milestone is achieved has not been achieved with respect to Compound, then at the time of the payment of the milestone payment for such achieved milestone event, CoLucid shall pay to
Lilly the previously listed and unpaid payments for such unmet milestone events, up to and including filing of an NDA in the US or its equivalent in the EU in a Major Market or Japan. Subsequent milestone event payments will be paid within thirty
(30) days by CoLucid to Lilly as such milestone events are achieved. 
 (d) Royalty Payments from CoLucid to
Lilly. CoLucid shall pay Lilly a royalty on Net Sales of Product by Permitted Sellers during the Royalty Term as follows: 
  

					
	 Net Sales for Each Fiscal

Year of CoLucid
	  	Royalty Rate	 
	 [*]
	  	 	8	% 
	 [*]
	  	 	11	% 

 Beginning with the year in which NDA submission occurs (such year being the base year from which future
adjustments will be made), the Net Sales tiers specified above shall be adjusted each January 1 in accordance with the U.S. Bureau of Labor Statistics’ United States consumer price index for the then-just-ended calendar year. 

If in any country any person other than CoLucid or its Affiliates or sublicensees introduces any final form human pharmaceutical composition
or preparation, in any dosage, strength or size, for any mode of administration, containing a generic equivalent of Compound, as applicable, which generic equivalent has received all authorizations and approvals required by Applicable Laws for such
sale, and sales of such generic equivalent represent at least [*] of total sales in such country on a unit basis, then the royalty rate payable by CoLucid with respect to Net Sales of that Product in such country shall be reduced [*]. 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

10 

 [*] 

In the event practice or use of a Licensed Patent consistent with the terms of this Agreement results in (i) an infringement claim by a
third party or (ii) a desire on the part of CoLucid to enter into a third party license agreement based on its good faith opinion that an infringement against such third party’s patent(s) may occur without such a license and notice to and
concurrence by Lilly to such third party license (which concurrence shall not be unreasonably withheld), CoLucid shall be entitled to credit, against royalties otherwise owed to Lilly under Section 3.1(d) above, [*] of any amount actually paid
by CoLucid to such third party for a license under a patent owned or controlled by such third party; provided, however, that CoLucid may only credit against royalties otherwise due in a calendar year such amounts that (i) are directly
attributable to the manufacture or sale of Product (and not with respect to any other uses or products); and (ii) that in total for such calendar year do not exceed [*] of Net Sales. Except as set forth in this paragraph, CoLucid shall be
solely responsible for any royalties or other payments due a third party for Product. 
 Lilly acknowledges that CoLucid may seek to enter
into out-licensing, commercialization, and sublicensing transactions as described in Section 2.4 or other collaboration arrangements. In the event that CoLucid seeks to enter such collaboration arrangements and determines in good faith that it
is not able to do so on terms that are reasonably satisfactory to CoLucid based in part on the amount of the royalty rates set forth in Section 3.1(d) and related terms of this Agreement, then CoLucid may give notice of such determination to
Lilly. [*] 
 CoLucid shall pay royalties due under this Section 3.1(d) concurrently with the remittance of the royalty report in
accordance with Section 3.2. All amounts payable to Lilly under Section 3.1 shall be paid in U.S. dollars by Federal Reserve electronic wire transfer in immediately available funds to an account designated in writing by Lilly (unless
otherwise instructed by Lilly in writing). 
 3.2 Record Retention, Royalty Reports, and Royalty Payment Schedule. CoLucid shall keep
(and shall cause its Affiliates and require its sublicensees to keep) complete and accurate books and records that are necessary to ascertain CoLucid’s compliance with this Agreement including such records as are necessary to verify royalty
payments owed under Section 3.1(d). Such records shall be kept in accordance with 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

11 

 
GAAP and CoLucid’s or its sublicensees’ internal practices and procedures, consistently applied. Beginning with the First Commercial Sale of a Product, CoLucid shall furnish Lilly
with a quarterly report on Net Sales of Product within sixty (60) days after the end of each Calendar Quarter. Such report shall include a written report detailing: (i) the Net Sales of Product for the previous Calendar Quarter, broken
down by country and between CoLucid and any Permitted Sellers, (ii) the royalty payment that is due and payable, and (iii) the basis for calculating such royalty payment. CoLucid will mail such reports to the attention of: Eli Lilly and
Company, Lilly Royalty Administration in Finance, Drop Code 1064, Lilly Corporate Center, Indianapolis, Indiana, 46285 (unless otherwise instructed by Lilly in writing). The amount of royalty payment due to Lilly shall be paid by CoLucid
concurrently with the remittance of each royalty report (that is, within sixty (60) days of the end of each Calendar Quarter). 

3.3 Milestone Payments are not Creditable. CoLucid’s milestone payments under this Article 3 are not creditable against
CoLucid’s royalty obligations to Lilly under this Article 3.  
 3.4 Audits. Lilly will have the right,
during regular business hours and upon reasonable advance notice, to have such books and records of CoLucid described in Section 3.2 audited no more than one (1) time per calendar year so as to verify CoLucid’s compliance with the
terms of this Agreement. Such audit may cover the two (2) calendar years preceding the date of the request for such audit and may not cover any other calendar year; provided, however that Lilly may audit a given calendar year only once.
Such audit right shall continue for two (2) calendar years following termination of the Agreement. 
 Lilly will keep
confidential any information obtained during such audit. The cost of such audit will be borne by Lilly; however, if as a result of such audit the Parties agree that the amount of royalties owed to Lilly is greater than or equal to five percent
(5%) or more than the amount of royalties paid for the calendar year that is the subject of the audit, the reasonable cost of the audit will be borne by CoLucid. Within thirty (30) days after both Parties have received a copy of an audit
report, CoLucid or Lilly, as appropriate, will compensate the other Party for payment errors or omissions revealed by the audit. CoLucid will include in all sublicenses granted in accordance herewith, and any other agreements enabling a Third Person
to be a Permitted Seller, an audit provision substantially similar to the foregoing requiring such Permitted Seller to keep full and accurate books and records relating to the Product and granting Lilly the right to audit the accuracy of the
information reported by the sublicensee in connection therewith. 
 3.5 Taxes and Currency. All payments made under this Agreement
shall be in United States dollars. Any and all taxes levied on any royalty or milestone payments made by CoLucid to Lilly under this Agreement shall be the liability of and paid by Lilly. CoLucid shall be responsible for all other taxes. If laws or
regulations require the withholding of such taxes, the taxes will be deducted by CoLucid from the payment and remitted by CoLucid to the proper tax authority, provided that CoLucid will furnish Lilly with a copy of the official tax receipt on such
withholdings as soon as practicable after such withholding, and give Lilly such assistance, at Lilly’s expense, as 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

12 

 
may be reasonably necessary to enable or assist Lilly to claim exemption or take credit therefrom. Proof of payment shall be provided to Lilly within sixty (60) days after payment.
CoLucid will cooperate, at Lilly’s expense, in pursuing tax refunds, if such refund is appropriate in Lilly’s determination. 

3.6 Late Payment. Any amounts not paid by CoLucid when due under this Agreement will be subject to interest from and
including the date payment is due through and including the date upon which Lilly has collected the funds in accordance herewith at a rate equal to the lesser of (i) the sum of five percent (5%) plus the prime rate of interest quoted in
the Money Rates (or equivalent) section of the Wall Street Journal per annum, calculated daily on the basis of a three hundred sixty (360) day year, or (ii) the maximum interest rate allowed by law. 

ARTICLE 4 
 INITIATION
AND CONDUCT OF DEVELOPMENT 
 AND COMMERCIALIZATION OF PRODUCT 

4.1 CoLucid and Lilly Representatives. Promptly (and no later than thirty (30) days) after the Closing Date, CoLucid shall
designate in writing the CoLucid representative that shall have the responsibility of communicating with Lilly personnel regarding transition support, development and commercialization of Product under this Agreement (including the provision of that
individual’s name, job title, fax and phone number). CoLucid may change such representative from time to time by written notice to Lilly containing the name and contact information for the new representative. Likewise, Lilly will promptly (and
no later than thirty (30) days) after the Closing Date, designate in writing the Lilly representative that shall have the responsibility of communicating with CoLucid under this Agreement (including the provision of that individual’s name,
job title, fax and phone number). Lilly may change such representative from time to time by written notice to CoLucid containing the name and contact information for the new representative. 

4.2 Transfer of Patent Files, Lilly Know-How and Transition Support. 

(a) Transfer of Patent Files. Lilly shall deliver, or instruct Lilly’s counsel to deliver, to CoLucid copies of the
original files of Lilly or Lilly’s counsel relating to the Licensed Patents, it being understood that Lilly promptly shall initiate the delivery process and that all such copies shall be delivered to CoLucid within thirty (30) days after
the Closing Date. Lilly also shall promptly forward, and/or instruct Lilly’s counsel to forward, to CoLucid any correspondence or other communication relating to the Licensed Patents that Lilly or any counsel employed by Lilly may receive from
any patent office in connection with the Licensed Patents. 
 (b) Provision of Lilly Know-How. Within ninety
(90) days of the Closing Date, Lilly shall use its commercially reasonable efforts to supply CoLucid with all Lilly Know-How identified on Exhibit D.  

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

13 

 (c) Transition Support. The Parties agree to work in good faith to
complete the provision of Lilly Know-How identified on Exhibit D to CoLucid within ninety (90) days of the Closing Date (“Transition Period”). In addition, during this time, Lilly will grant CoLucid
access, during normal business hours, to appropriate Lilly personnel for reasonable consultation related to the Lilly Know-How. Except as set forth in Section 4.2(d) below, such access to Lilly personnel during the Transition Period is at no
cost to CoLucid, but shall not exceed a total of one hundred (100) Lilly person hours. Lilly shall have no obligation to provide support of any type beyond the 100 hours mentioned above or after the Transition Period. However, if Lilly agrees
to provide any additional support, CoLucid shall promptly pay Lilly (i) an amount equal to two hundred seventy-five dollars ($275) per hour for each such hour of services provided by Lilly, and (ii) the expenses set forth in
Section 4.2(d). Lilly believes that the information listed on Exhibit D represents all of the documents and Lilly-Know How that are in Lilly’s possession and that would be useful or relevant to CoLucid. If CoLucid has a significant
need for access to any Lilly documents or Lilly Know-How not listed on Exhibit D, it may request that Lilly provide such information, in which case Lilly will use its reasonable efforts to locate and provide such information, at
CoLucid’s expense. It is understood that any such requests should be of an infrequent and unusual nature, and that all reasonable efforts should be taken to avoid additional substantial burden on Lilly. CoLucid has advised Lilly that CoLucid
may desire to retain the services of Dr. Nabih Ramadan, who has served as a consultant to Lilly. Lilly has no objection to Dr. Ramadan providing such services, and Lilly agrees to confirm this in writing to Dr. Ramadan promptly upon
the request of Dr. Ramadan or CoLucid. 
 (d) Payment of Expenses. CoLucid will reimburse Lilly, within
thirty (30) days of receipt of a Lilly invoice (together with proper supporting documentation), all of the reasonable, actual travel and associated accommodation and meal expenses of Lilly personnel who travel upon CoLucid’s request in
connection with the provision of transition support.  
 4.3 CoLucid’s Obligation to Develop Compound and Product.
CoLucid shall use Diligence to develop Product and obtain Regulatory Approval in all Major Markets. CoLucid shall be responsible (financially and otherwise) for all further development (pre-clinical and clinical) for Product and Lilly shall have no
obligations with respect thereto. CoLucid or its sublicensees shall have responsibility for seeking all necessary Regulatory Approvals to develop the Product, and CoLucid or its sublicensees, shall hold legal title to all Applications for Marketing
Authorizations within the Territory, and shall assume full responsibility for the clinical protocols developed in support of such Applications for Marketing Authorization. Lilly shall have no financial obligation relating to Compound or Product.
CoLucid, itself or through its sublicensees, shall use Diligence in researching and developing the Product and otherwise carrying out its duties as contemplated under this Agreement. CoLucid will be responsible for all regulatory requirements during
development and commercialization of the Compound and Product.  

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

14 

 4.4 CoLucid Obligation to Update Lilly of Product Development Progress. At least once
every year, the CoLucid representative shall provide the Lilly representative with a copy of the then current Development Plan and a summary of the activities conducted during the preceding year. In addition, at least once per year CoLucid shall
provide a copy of the detailed end of year FDA written reports describing the progress made in implementing the Development Plan. Each such report shall include with respect to the applicable one (1) year period a description of the research
and development activities conducted both in the United States and outside the United States with respect to the Product, as well as any amendments or revisions to the Development Plan. CoLucid shall provide Lilly with regular telephonic updates
on the progress made in implementing the Development Plan and other information as Lilly may reasonably request. 
 4.5
CoLucid’s Commercialization Obligation. 
 (a) If the Product receives Regulatory Approval in a given
country, CoLucid shall use Diligence to commercialize the Product in such country. 
 (b) CoLucid Obligation to Notify,
and Lilly’s Right to Terminate for Failure of CoLucid to Market Product. CoLucid shall promptly notify Lilly if CoLucid decides: 

(i) not to file for Regulatory Approval of or market Product in a Major Market; 

(ii) to discontinue, for reasons other than Force Majeure, the marketing of Product in a Major Market; and/or 

(iii) not to resume the marketing of Product in a Major Market following the expiration of a Force Majeure event. 

Such notice or failure so to file or market, as the case may be, shall be deemed a material breach under Section 11.2. 

4.6 Adverse Event Reporting. CoLucid agrees to report Adverse Events that occur during the development and marketing of Product to the
relevant regulatory authorities promptly according to the Applicable Laws. CoLucid will be responsible for all safety and pharmacovigilance activities under Applicable Laws after the Closing Date. 

4.7 Governmental Filings. Lilly and CoLucid each agree to prepare and file whatever filings, requests or applications are required to
be filed with any governmental authority in connection with the transfer of rights in Article 2 of this Agreement and to cooperate with one another as reasonably necessary to accomplish the foregoing. 

4.8 Compliance with Law. CoLucid will comply in all material respects with all Applicable Laws relating to its development,
manufacture, distributing, marketing, promotion, selling, importing and exporting of the Product. CoLucid agrees 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

15 

 
and acknowledges that as holder of the regulatory documents with respect to Product, it will have sole responsibility for, among other things, Adverse Event reporting and all other regulatory
reporting and regulatory document maintenance obligations. 
 ARTICLE 5 

SUPPLIES OF COMPOUND 

5.1 Transfer of Compound Supply. Lilly hereby assigns, transfers, and conveys to CoLucid, effective as of the Closing Date, all of
Lilly’s right, title, and interest in and to the Lilly supply of Compound and Compound intermediates, described in Exhibit B (“Compound Supply”), and within ninety (90) business days of the Closing Date, or
on such other delivery schedule reasonably acceptable to each of the Parties, Lilly will transfer to CoLucid Compound Supply as well as all existing documentation, methods and standards related to the Compound Supply. All Compound Supply is being
transferred “AS IS” without any warranty that the Compound Supply is suitable for human testing. Once possession of the Compound Supply is transferred to CoLucid, CoLucid shall be responsible for performing, or having a Third Person
perform, all quality control, quality assurance, and analytical assays (including developmental, release, related substances, stability, toxicology dosage form and end of study assays). In addition, CoLucid shall comply with any restriction on use
of Compound Supply set forth on Exhibit B. 
 5.2 Additional Supply of Compound. Except as set forth in Section 5.1,
CoLucid shall, at its own expense, provide all quantities of Compound, Compound intermediates or Product that CoLucid needs to accommodate its development and commercialization efforts under this Agreement. CoLucid acknowledges that Lilly will not
supply any quantities of Compound or Compound intermediates other than that set forth on Exhibit B. 
 ARTICLE 6 

INTELLECTUAL PROPERTY 

6.1 Intellectual Property Maintenance. Licensed Patents shall be filed, prosecuted and maintained worldwide by a Third Person patent
counsel designated by CoLucid and reasonably acceptable to Lilly. CoLucid shall have the ultimate responsibility for and control over such matters and shall bear all expenses incurred in filing, prosecuting and maintaining Licensed Patents. CoLucid
or its designee shall keep Lilly informed of the filing, prosecution and maintenance of Licensed Patents, and shall furnish to Lilly copies of substantive documents (e.g., office actions and responses) relevant to any such efforts in advance
with sufficient time for Lilly to review and provide comments on such documents, and shall in good faith take such comments into account. If CoLucid decides to allow any Licensed Patent to lapse or if CoLucid wishes to abandon any Licensed Patent,
CoLucid shall notify Lilly in writing not less than sixty (60) days prior to taking such action, and Lilly shall have the right to assume the responsibility for such Licensed Patents, and if Lilly does so, then CoLucid shall

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

16 

 
surrender to Lilly its rights under Article 2 under the patent or patent application in the country or countries so affected and Lilly may assume control of the same at Lilly’s sole expense
(it being understood that all other rights under the license to such Licensed Patent in other countries and to all other Licensed Patents under Article 2 continue). 

6.2 Enforcement of Intellectual Property Rights. CoLucid and Lilly will promptly notify the other of any infringement or
misappropriation or suspected infringement or misappropriation that may come to its notice of any intellectual property rights relating to the Product, including, without limitation, the Licensed Patents and Lilly Know-How, and will provide the
other Party with information with respect thereto. If a Third Person infringes any Licensed Patent or Lilly Know-How, CoLucid will have the first right (but not the obligation), at its own expense, to pursue any and all injunctive relief, and any or
all compensatory and other remedies and relief (collectively, “Remedies”), against such Third Person, and Lilly will have the right to participate in such action at its own expense. Should CoLucid determine not to pursue
Remedies with respect to any such infringement or misappropriation of Licensed Patents or Lilly Know-How within sixty (60) days after receipt of written notice from Lilly requesting CoLucid to do so, then Lilly will have the right (but not the
obligation), at its own expense, to pursue Remedies against such Third Person, and CoLucid shall have the right to participate in such action at its own expense. 

6.3 Assistance and Cooperation. If a Party pursues Remedies hereunder with respect to infringement or misappropriation of CoLucid
Technology, Licensed Patents or Lilly Know-How, the other Party will use all reasonable efforts to assist and cooperate with the Party pursuing such Remedies, including joining in any action or providing a power of attorney if necessary. Each Party
will bear its own costs and expenses relating to such pursuit. Any damages or other amounts collected will be distributed, first, to the Party that pursued Remedies to cover its costs and expenses; and second, to the other Party to cover its costs
and expenses, if any, relating to the pursuit of such Remedies; and any remaining amount will be distributed to the Party that pursued the Remedies, provided that any recovery by CoLucid attributable to lost sales shall be deemed Net Sales
hereunder, and a royalty paid thereon. 
 6.4 Settlement of Litigation. No settlement, consent judgment or other final disposition of
an action for infringement or validity may be entered into by a Party as to any Licensed Patent or Lilly Know-How without the other Party’s prior written consent, which consent shall not be unreasonably withheld. 

6.5 Infringement of Third Person Rights. If a Third Person institutes a patent, trade secret or other infringement suit against CoLucid
or a Permitted Seller during the term of this Agreement, alleging that the manufacture, marketing, sale, use or importation of the Product infringes one or more patent or other intellectual property rights held by such Third Person, then CoLucid
will have the sole right (but not the obligation), at its sole expense, to assume direction and control of the defense of such claims. At CoLucid’s request, Lilly will provide reasonable assistance in connection with the defense of such claims,
and CoLucid will reimburse Lilly for all documented reasonable expenses incurred by Lilly in connection therewith. CoLucid will not have 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

17 

 
the right to settle or otherwise dispose of any such claim without the consent of Lilly, which consent will not be unreasonably withheld, unless there is no finding or admission of either
infringement by or non-validity of any Licensed Patent or Lilly Know-How. 
 6.6 CoLucid Technology. CoLucid will be the sole owner
of the CoLucid Technology. CoLucid shall bear all expenses incurred in preparing, filing, prosecuting and maintaining all patent applications and patents that encompass any CoLucid Technology. CoLucid or its designee shall keep Lilly reasonably
informed of the filing, prosecution and maintenance of patents and patent applications encompassing any CoLucid Technology. 
 6.7 Failure
to Maintain Applications or Patents. If CoLucid decides not to maintain or continue to prosecute any patent application or patent encompassing CoLucid Technology, it shall give Lilly reasonable written notice to this effect. After such notice,
Lilly may, at its expense, maintain or continue to prosecute such application or patent, and CoLucid shall assign such application or patent to Lilly. 

6.8 Patent Reporting. Within sixty (60) days after each Calendar Year, CoLucid shall provide Lilly with a written report
describing the status of all Licensed Patents, including the patent country, patent and application numbers, filing date, issue date, expiration date, and any other relevant information requested by Lilly. Such report shall be mailed to Eli Lilly
and Company, Lilly Royalty Administration in Finance, Drop Code 1064, Lilly Corporate Center, Indianapolis, Indiana, 46285 (unless Lilly advises otherwise in writing) with a copy to the General Patent Counsel. 

6.9 Trademarks. CoLucid will own and be responsible for all trademarks related to its marketing of Product and will be responsible, in
its sole discretion, for registering, defending and maintaining such trademarks. 
 6.10 Patent Cooperation. Each Party hereby agrees
to make its employees, agents and consultants reasonably available to the other Party (or the other Party’s authorized attorneys, agents or representatives) at the other Party’s expense, to the extent reasonably necessary to enable the
Party responsible for prosecuting the Licensed Patents to undertake preparation, filing, prosecution and maintenance of the Licensed Patents. 

6.11 Patent Term Extensions and Certifications. 

(a) If requested by CoLucid, Lilly shall cooperate in obtaining patent term restoration, supplementary protection
certificates or their equivalents, and patent term extensions (including but not limited to those available under the Hatch-Waxman Act) of Licensed Patents covering or claiming Products in any country and/or region where applicable. Lilly shall
provide all reasonable assistance requested by CoLucid, including permitting CoLucid to proceed with applications for such in the name of Lilly, if reasonably deemed appropriate by CoLucid, and executing documents and authorizations as required, and
providing any relevant information to CoLucid. 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

18 

 (b) CoLucid shall in its sole discretion determine which, if any, Licensed
Patent it will apply to extend. 
 (c) If requested by CoLucid, Lilly shall cooperate in maintaining with the
applicable government or regulatory authorities during the Term correct and complete listings of applicable Licensed Patents for Products being commercialized, including all “Orange Book” listings required under the Hatch-Waxman Act. 
 (d) CoLucid shall be responsible for any out-of-pocket expenses
incurred by Lilly in providing the foregoing cooperation and assistance pursuant to sub-paragraphs 6.11(a) and (c). 
 ARTICLE 7 

CONFIDENTIALITY 
 7.1
Confidential Information. The Parties agree that, unless the Receiving Party obtains the prior written consent of the Disclosing Party, at all times during the term of this Agreement and for a ten (10)-year period following its expiration or
earlier termination, the Receiving Party will keep completely confidential, will not publish or otherwise disclose and will not use directly or indirectly for any purpose other than as contemplated by this Agreement any Confidential Information of
the Disclosing Party, whether such Confidential Information was received by the Receiving Party prior to, on or after the Original Effective Date. Confidential Information exchanged under the Confidentiality and Non-Use Agreement dated
September 21, 2004 shall also be included in this Section 7.1. 
 7.2 Limited Disclosure Permitted. Each Party may disclose
Confidential Information to the extent that such disclosure is: 
 (a) required by law, in the opinion of legal
counsel to the Receiving Party; provided, however, that the Receiving Party will first have given reasonable notice to the Disclosing Party (if practicable) and given the Disclosing Party a reasonable opportunity to obtain a protective order or
confidential treatment requiring that the Confidential Information and documents that are the subject thereof be held in confidence by the recipient or, if disclosed, be used only for purposes required by such law; provided further, however, that if
a protective order is not obtained, the Confidential Information so disclosed will be limited to that information that is legally required to be disclosed as required by applicable law; 

(b) made by the Receiving Party to a governmental or regulatory authority, including FDA, as required to conduct
Clinical Trials or obtain or maintain marketing approval for the Product, provided that reasonable effort will be taken to ensure confidential treatment of such information; 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

19 

 (c) made by the Receiving Party to a Third Person as may be necessary or
useful in connection with the manufacture, development and commercialization of the Product, provided that the Receiving Party will in each case obtain from the proposed Third Person recipient a written confidentiality agreement containing
confidentiality and non-use obligations no less protective than those set forth in this Agreement; 
 (d) made by the
Receiving Party to a United States or foreign tax authority; 
 (e) made by the Receiving Party to its representatives
or to Third Persons in connection with any financing, partnering or sublicensing activities, or potential Change of Control transactions, involving the Receiving Party; provided, however, that: (i) each such representative or Third Person has a
need to know such Confidential Information and has an obligation to maintain the confidentiality of such information, (ii) the Receiving Party informs each representative or Third Person receiving Confidential Information of its confidential
nature, and (iii) the Receiving Party will be responsible for any breach of this Article 7 by any of its representatives or such Third Persons to the same extent as if the breach were by the Receiving Party; 

(f) made by a Receiving Party or any representative of the Receiving Party in the filing or publication of patents or
patent applications relating to Licensed Patents, Lilly Know-How, CoLucid Technology or any invention relating to the Compound or Product, to the extent such disclosure in the filing or publication of the patent or patent application is reasonably
necessary for support of the patent or patent application; 
 (g) made by Lilly to its attorneys, accountants,
consultants and other professionals to the extent necessary to obtain their services in connection with monitoring Lilly’s investment in CoLucid; 

(h) made by Lilly to any Affiliate of Lilly in the ordinary course of business, provided that Lilly remains responsible
for any breach by its Affiliates of this Section 7.2.; or 
 (i) made by a Receiving Party in order to
comply with applicable securities law disclosure requirement or any disclosure requirements of any applicable stock market or securities exchange. 

7.3 Disclosure of Agreement. Except as contemplated herein, neither Party shall disclose this Agreement (nor a redacted version
thereof) to any Third Person without the prior written consent of the other Party. Without limitation, these prohibitions apply to press releases, annual reports, prospectuses, public statements, educational and scientific conferences, promotional
materials, governmental filings and discussions with public officials, securities analysts and the media. However, subject to the requirements for review and approval that follow, this provision does not apply to a

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

20 

 
disclosure regarding this Agreement, which counsel to a Party has advised is required by Applicable Laws, to regulatory agencies such as the FDA, Securities and Exchange Commission
(“SEC”), Federal Trade Commission or Department of Justice or any applicable stock market or securities exchange. This includes requests for a copy of this Agreement or related information by tax authorities.
Notwithstanding the foregoing, Receiving Party may disclose the terms contained in this Agreement to Third Persons in connection with any activities or transactions involving the Receiving Party as set forth in Section 7.2(e). Any press release
announcing the signing of this Agreement shall be mutually approved by the Parties. 
 If any Party to this Agreement determines a
release of information regarding the existence or terms of this Agreement is required by Applicable Laws, prior to any release of such information, that Party will notify the other Party in writing as soon as practical and provide as much detail as
possible in relation to the disclosure required and, where possible under Applicable Laws, will endeavor in good faith to provide the other Party with a minimum of five (5) business days to review the proposed public statement. The Parties will
then discuss what information, if any, will actually be released and that Party shall obtain the other Party’s prior written consent or conduct any actions it may reasonably take to prevent or limit the requested disclosure. In addition, Lilly
shall have the right to review and comment on a redaction of this Agreement required by the SEC or other agencies and CoLucid shall use good faith in taking Lilly’s comments into account prior to releasing the redaction to the SEC or such
agency. 
 7.4 Survival. The confidentiality and non-use obligations of this Article 7 shall survive the termination or expiration of
this Agreement.  
 ARTICLE 8 

REPRESENTATIONS, WARRANTIES, COVENANTS, AND DISCLAIMERS 

8.1 No Litigation, Infringement, etc. Each Party represents that, to the best of its knowledge as of the Original Effective Date, there
is no litigation or proceeding pending or threatened against or involving such Party in any court or before any agency or regulatory body which could adversely affect such Party’s ability or right to carry out the transactions contemplated by
this Agreement. Lilly represents and warrants that there is no pending litigation or proceeding which alleges that any of its activities relating to the Licensed Patents, the Lilly Know-How or the Compound have violated any of the intellectual
property rights of any other person (nor has it received any written communication threatening such litigation or proceeding). 
 8.2 No
Debarment. Each Party represents and warrants to the other that it will comply at all times with the provisions of the Generic Drug Enforcement Act of 1992 and upon request each Party will certify in writing to the other Party that neither such
Party, its employees, nor any Person providing services for such Party under this Agreement has been debarred under the provisions of such Act.  

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

21 

 8.3 Corporate Existence. As of the Original Effective Date, each Party represents and
warrants to the other that it is a company duly organized, validly existing, and, if relevant in its jurisdiction of formation, in good standing under the laws of the jurisdiction in which it is formed. 

8.4 Authority to Execute and Perform. As of the Original Effective Date, each Party represents and warrants to the other that it:

 (a) has the power and authority and the legal right to enter into this Agreement and perform its obligations
hereunder; 
 (b) has taken all necessary company action on its part required to authorize the execution and delivery
of this Agreement; and 
 (c) has duly executed and delivered the Agreement, which constitutes a legal, valid, and
binding obligation of it and which is enforceable against it in accordance with the Agreement’s terms. 
 8.5 Additional Lilly
Representations, Warranties and Covenants. 
 (a) Development Activities. As of the Restatement Effective Date, Lilly
represents and warrants to CoLucid that it is not presently developing or participating in the development of, and has no present plans to develop or participate in the development of, any
5-HT1F Selective Compound (as defined below). In addition, Lilly agrees that it will not undertake any human clinical testing with respect to any 5-HT1F Selective Compound for treatment or prevention of migraine or headache pain, nor grant any such rights to a Third Person, for a period of five (5) years from the Restatement Effective Date,
so long as this Agreement is in full force and effect. Notwithstanding the foregoing, this provision shall not apply (i) in the event of any merger or acquisition involving Lilly and another company where such company is engaged in such
research or (ii) to any 5-HT1F Selective Compound with respect to which Lilly acquired rights via a licensing transaction or otherwise after the Restatement Effective Date. As used herein,
“5-HT1F Selective Compound” shall mean a compound that has functionally agonistic activity at the 5-HT1F receptor site and such
activity is the principal clinically desirable pharmacological activity. For the avoidance of doubt, Compound is included within the definition of 5-HT1F Selective Compound. It is understood
that, subject to Section 2.1, Lilly may (i) at any time now or in the future have or pursue development efforts for any indication with respect to compounds that principally target other 5-HT receptors and, (ii) following the five
year period referenced above, pursue development, including human testing, of 5-HT1F Selective Compounds, other than Compound, for any indication. 

(b) Patents. Lilly represents and warrants to CoLucid as of the Original Effective Date that Lilly owns the Licensed Patents.
Nothing in this Agreement shall constitute a representation or warranty by Lilly that the Licensed Patents are or will be valid or that exercise of the Licensed Patents will not infringe the intellectual property rights of others. In the event Lilly
subsequently discovers that it Controls as of the 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

22 

 
Original Effective Date any other patent rights other than the Licensed Patents that are necessary to the exercise of the Licensed Patents then Lilly will, without further consideration, amend
this Agreement to include such patent rights within the scope of the Licensed Patents. 
 (c) Purchase Entirely for Own
Account. This Agreement is made with Lilly in reliance upon Lilly’s representation to CoLucid, which by Lilly’s execution of this Agreement Lilly hereby confirms, that the Shares to be purchased by Lilly will be acquired for investment
for Lilly’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that Lilly has no present intention of selling, granting any participation in, or otherwise distributing the same. By
executing this Agreement, Lilly further represents that Lilly does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of
the Shares. 
 (d) Reliance upon Lilly’s Representations. Lilly understands that the Shares are not registered under the
Securities Act of 1933, as amended (the “Securities Act”) on the ground that the sale provided for in this Agreement and the issuance of Shares hereunder is exempt from registration under the Securities Act, pursuant to
Section 4(2) thereof, and that CoLucid’s reliance on such exemption is predicated on Lilly’s representations set forth herein. Lilly realizes that the basis for the exemption may not be present if, notwithstanding such
representations, Lilly has in mind merely acquiring the Shares for a fixed or determinable period in the future, or for a market rise, or for sale if the market does not rise. Lilly has no such intention. 

(e) Receipt of Information. Lilly represents that Lilly has had an opportunity to ask questions and receive answers from CoLucid
regarding the terms and conditions of the offering of the Shares and the business, properties, and financial condition of CoLucid and to obtain additional information necessary to verify the accuracy of any information furnished to Lilly or to which
Lilly had access; the foregoing, however, does not limit or modify the representations and warranties of CoLucid in this Article 8 or the right of Lilly to rely thereon. 

(f) Investment Experience. Lilly represents that Lilly is experienced in evaluating and investing in private placement
transactions of securities of companies in a similar stage of development and acknowledges that Lilly is able to fend for itself, can bear the economic risk of Lilly’s investment, and has such knowledge and experience in financial and business
matters that Lilly is capable of evaluating the merits and risks of the investment in the Shares. 
 (g) Accredited Investor.
Lilly represents to CoLucid that Lilly is an “accredited investor” within the meaning of Rule 501 of Regulation D adopted pursuant to the Securities Act. 

(h) Restricted Securities. Lilly understands that the Shares may not be sold, transferred, or otherwise disposed of without
registration under the Securities Act or an exemption therefrom, and that in the absence of an effective registration statement 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

23 

 
covering the Shares or an available exemption from registration under the Securities Act, the Shares must be held indefinitely. In particular, Lilly is aware that the Shares may not be sold
pursuant to Rule 144 promulgated under the Securities Act unless all of the conditions of that Rule are met. Among the conditions for use of Rule 144 may be the availability of current information to the public about CoLucid. Such information
is not now available. 
 (i) Legends. To the extent applicable, each certificate or other document evidencing any of the Shares
shall be endorsed with the legends substantially in the form set forth below: 
 (i) The following legend under the Securities Act:

 “THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD,
TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT, OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL OR OTHER EVIDENCE, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT
REQUIRED.” 
 (ii) Any legend imposed or required by the CoLucid’s Bylaws or applicable state securities laws or any
agreements referred to in Section 3.1(a). 
 (j) Between the Original Effective Date and the Closing Date, Lilly shall use its
commercially reasonable efforts to preserve and maintain the Lilly Know-How, the Licensed Patents, and the Compound, and shall not enter into any agreement or arrangement with any Third Person which conflicts or is inconsistent with this Agreement.

 8.6 Additional CoLucid Representations, Warranties and Covenants. 

(a) Valid Issuance of Shares. The Shares that are being purchased by Lilly hereunder, when issued, sold and delivered in
accordance with the terms of this Agreement for the consideration expressed herein, will be duly and validly issued, fully paid, and nonassessable, and will be free of restrictions on transfer other than restrictions on transfer under this Agreement
and under applicable federal and state securities laws. 
 (b) Private Offering. Subject in part to the truth and accuracy of
Lilly’s representations set forth in this Agreement, the offering, sale and issuance of the Shares as contemplated by this Agreement are exempt from the registration requirements of the Securities Act and applicable state securities laws, and
neither CoLucid nor any authorized agent acting on its behalf will take any action hereafter that would cause the loss of such exemption. 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

24 

 8.7 DISCLAIMER OF IMPLIED WARRANTIES. EXCEPT AS EXPRESSLY PROVIDED IN THIS SECTION, LILLY
MAKES NO REPRESENTATION OR WARRANTY AS TO THE LICENSED PATENTS, LILLY KNOW-HOW, COMPOUND, COMPOUND SUPPLY OR PRODUCT, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, STATUTE, OR OTHERWISE, AND LILLY SPECIFICALLY DISCLAIMS ANY AND ALL
IMPLIED OR STATUTORY WARRANTIES INCLUDING WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT AND OF FITNESS FOR A PARTICULAR PURPOSE. FURTHER, EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY UNDER
THIS AGREEMENT, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, STATUTE, OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED OR STATUTORY WARRANTIES INCLUDING WARRANTIES OF MERCHANTABILITY AND OF FITNESS FOR A
PARTICULAR PURPOSE. Without limiting the foregoing, CoLucid acknowledges that it has not and is not relying upon any implied warranty of merchantability or of fitness for a particular purpose or otherwise, or upon any representation or warranty
whatsoever as to the prospects (financial, regulatory or otherwise), validity, or likelihood of success of Compound or Product after the Original Effective Date. 

8.8 DISCLAIMER OF INCIDENTAL AND CONSEQUENTIAL DAMAGES. NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL,
CONSEQUENTIAL, OR SPECIAL DAMAGES, OR FOR LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTHING IN THIS SECTION IS INTENDED TO LIMIT OR RESTRICT THE
INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY. 
 ARTICLE 9 

REGISTRATION AND INFORMATION RIGHTS 

9.1 Piggy-Back Registration. If CoLucid intends to register its securities in a public offering of securities solely for cash (other
than certain registrations relating to the sale of securities to employees or to a Rule 145 transaction or a registration on any form that does not include substantially the same information as would be required to be included in a registration
statement covering the sale of the Shares), CoLucid will give Lilly notice of such registration and, upon the prompt request of Lilly, CoLucid will cause to be registered all of the Shares that Lilly has requested to be included in such
registration. If the registration involves an underwriting, Lilly will enter into an underwriting agreement with the underwriter, containing customary provisions, including indemnification and, if the underwriter determines that the number of shares
in the underwritten registration must be limited, the underwriter or CoLucid may limit some or all of the Shares to be included in such registration. Lilly agrees that the registration rights described above are subordinate to the registration
rights to be granted in the Next 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

25 

 
Financing, and that CoLucid may grant at any time registration rights which are senior to, on par with, or junior to Lilly’s rights. Lilly will furnish such information as may be reasonably
requested in connection with the registration and will enter into a customary indemnification agreement with CoLucid. Further, Lilly will bear all of the fees and expenses of its counsel and all other customary “selling expenses.” The
provisions in this Section 9.1 shall survive the expiration or termination of this Agreement. 
 9.2 Information Rights. CoLucid
will provide to Lilly, within 180 days after the end of each fiscal year, audited financial statements consisting of a balance sheet as of the end of such year, statements of income and of cash flows for such year and a statement of
stockholders’ equity as of the end of such year. CoLucid will not be obligated to provide information that CoLucid reasonably determines to be a trade secret or confidential. All information provided to Lilly under this Section 9.2 shall
be considered Confidential Information of CoLucid. The rights and obligations under this Section 9.2 will terminate upon the first to occur of the following: (i) CoLucid’s initial registered public offering, (ii) CoLucid becomes
a reporting company under the United States Securities Exchange Act of 1934, as amended, (iii) CoLucid is the subject of a Change of Control, or (iv) Lilly no longer holds any Shares. 

ARTICLE 10 

INDEMNIFICATION 
 10.1
Indemnification. 
 (a) CoLucid’s Obligation. Except to the extent such Damages are due to negligence, gross
negligence or willful misconduct by Lilly, its Affiliates or their officers, directors, employees or agents, CoLucid shall defend, indemnify and hold harmless Lilly and its Affiliates and their officers, directors, employees and agents against any
and all Damages incurred by any of them resulting from or arising out of: 
 (i) any material breach of any
representation or warranty made by CoLucid in this Agreement; 
 (ii) the handling, possession, development,
manufacturing, marketing, distribution, promotion, sale or use of the Product by CoLucid or a Permitted Seller;  

(iii) the exercise of any right(s) under the Licensed Patents or Lilly Know-How by CoLucid, its Affiliates, Permitted
Sellers and any permitted sublicensees; 
 (iv) CoLucid’s failure to comply in all material respects with
Applicable Laws in connection with the performance of its obligations hereunder; or 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

26 

 (v) Any other activities conducted by CoLucid, its Affiliates, Permitted
Sellers and any permitted sublicensee with respect to Compound conducted after the Closing Date. 
 (b) Lilly’s
Obligation. Except to the extent such Damages are due to negligence, gross negligence or willful misconduct by CoLucid, its Affiliates or their officers, directors, employees or agents, Lilly shall defend, indemnify and hold harmless CoLucid,
its Affiliates and their officers, directors, employees and agents against any and all Damages incurred by any of them resulting from or arising out of: 

(i) any material breach of any representation or warranty made by Lilly in this Agreement; 

(ii) any activities conducted by or on behalf of Lilly with respect to rights reserved under Section 2.2; 

(iii) the exercise of any right(s) under the CoLucid Technology by Lilly or its Affiliates pursuant to
Section 11.3(c); 
 (iv) the exercise by Lilly of any right(s) under the Licensed Patents or Lilly Know-How prior
to the Closing Date; and 
 (v) the handling, possession, development, manufacture or use of Compound prior to the
Closing Date. 
 10.2 Notice and Opportunity To Defend. 

(a) Notice. Promptly after receipt by a Party hereto of notice of any claim which could give
rise to a right to indemnification pursuant to Section 10.1, such Party (the “Indemnitee”) will give the other Party (the “Indemnifying Party”) written notice describing the claim in reasonable
detail. The failure of an Indemnitee to give notice in the manner provided herein will not relieve the Indemnifying Party of its obligations under this Article 10, except to the extent that such failure to give notice materially prejudices the
Indemnifying Party’s ability to defend such claim. 
 (b) Defense of Action. In case any action
that is subject to indemnification under this Article 10 shall be brought against an Indemnitee and it shall give written notice to the Indemnifying Party of the commencement thereof, the Indemnifying Party shall be entitled to participate and, if
it so desires, to assume the defense with counsel reasonably satisfactory to such Indemnitee. After notice from the Indemnifying Party to the Indemnitee of its election to assume the defense, the Indemnifying Party shall not be liable to such
Indemnitee under this Article 10 for any fees of other counsel or any other expenses, in each case subsequently incurred by such Indemnitee in connection with the defense. 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

27 

 (c) Indemnitee’s Separate Counsel. Notwithstanding the foregoing, the
Indemnitee shall have the right to employ separate counsel and to participate in the defense of such action, and the Indemnifying Party shall bear the reasonable fees, costs and expenses of such separate counsel if: (i) the use of counsel
chosen by the Indemnifying Party to represent the Indemnitee would present such counsel with a conflict of interest, and the Indemnifying Party does not elect to engage new counsel without such a conflict; (ii) the Indemnifying Party shall not
have employed counsel reasonably satisfactory to the Indemnitee to represent the Indemnitee within a reasonable time after notice of the institution of such action; or (iii) the Indemnifying Party shall authorize the Indemnitee in writing to
employ separate counsel at the Indemnifying Party’s expense. 
 (d) Settlement. If an Indemnifying Party
assumes the defense of such action, no compromise or settlement thereof may be effected by the Indemnifying Party without the Indemnitee’s written consent, which consent shall not be unreasonably withheld or delayed, unless there is no finding
or admission of any violation of law or any violation of the rights of the Indemnitee and no effect on any other claims that may be made against the Indemnitee. In any event, the Indemnitee and the Indemnifying Party may participate, at their own
expense, in the defense of such asserted claim. 
 (e) Conduct of Defense. Notwithstanding anything to the
contrary in this Section 10.2, the Party conducting the defense of a claim will (1) keep the other Party informed on a reasonable and timely basis as to the status of the defense of such claim (but only to the extent such other Party is
not participating jointly in the defense of such claim), and (2) conduct the defense of such claim in a prudent manner. 

10.3 Survival. The provisions of this Article 10 will survive any termination or expiration of this Agreement. Each Indemnified
Party’s rights under this Article 10 will not be deemed to have been waived or otherwise affected by such Indemnified Party’s waiver of the breach of any representation, warranty, agreement or covenant contained in or made pursuant to this
Agreement, unless such waiver expressly and in writing also waives any or all of the Indemnified Party’s right under this Article 10. 

ARTICLE 11 
 TERM AND
TERMINATION 
 11.1 Term. The term of this Agreement will begin upon the Original Effective Date and, unless sooner terminated
under this Article 11, will continue in full force and effect on a country-by-country basis in the Territory until CoLucid and its Permitted Sellers have no remaining royalty payment obligations in a specific country under Section 3.1(d).
Upon expiration in a given country, CoLucid will have a fully paid up, perpetual, irrevocable license under the Lilly Know-How in such country. If the closing of the Next Financing (and therefore the Closing Date) shall not have occurred
within sixty (60) days after the Original Effective Date, then Lilly may deliver to 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

28 

 
CoLucid a notice referring to this Section 11.1 and requesting that the closing of the Next Financing (and the Closing Date) occur; and, if such closing does not occur within fifteen
(15) business days after CoLucid’s receipt of such notice, then this Agreement shall automatically terminate. 
 11.2
Material Breach by CoLucid. Upon any material breach of this Agreement by CoLucid, Lilly may, at its option, terminate this Agreement upon ninety (90) days written notice to CoLucid. Such termination shall become effective at the end of
such ninety (90) day period unless CoLucid cures such breach or violation during such ninety (90) day period; provided, however, in the case of a breach or violation that cannot be cured within such ninety (90) day period, Lilly may
terminate this Agreement following such ninety (90) day period only if CoLucid shall have failed to commence substantial remedial actions within such ninety (90) day period and to use best efforts to pursue the same. For sake of clarity,
CoLucid’s failure to Diligently develop or Diligently commercialize Product in accordance with this Agreement shall be deemed a material breach.  

Notwithstanding the foregoing, to the extent a material breach or material default of this Agreement by CoLucid affects CoLucid’s
performance and Lilly’s rights under this Agreement as it relates to one or more countries, but not all countries, Lilly may terminate this Agreement in accordance with this Section 11.2 as to the affected country or countries only, and in
such case this Agreement will remain in full force and effect with respect to the countries that are not terminated. Provided, however, that if such default relates to the US, Lilly may terminate this Agreement as to all countries. 

11.3 Rights Upon Termination by Lilly. If Lilly terminates this Agreement under Section 11.2 or 11.5, or CoLucid terminates this
Agreement under Section 11.4(a), then the following will take effect upon the effective date of such termination: 

(a) Reversion of Licensed Patents and Lilly Know-How and Direct License to Sublicensees. All rights under the Licensed
Patents and the Lilly Know-How granted by Lilly to CoLucid pursuant to Article 2 will terminate and all rights granted therein will immediately revert to Lilly with no further notice or action required on Lilly’s behalf; provided, however, that
if the termination relates only to a specific country, then only the license pertaining to such country will revert to Lilly hereunder. Any sublicensee under the rights granted to CoLucid hereunder which has not breached in any material respect its
sublicense shall be entitled to receive a license directly from Lilly granting rights substantially the same as those granted in each sublicense and containing obligations as a licensee similar to those set forth in this Agreement; provided,
however, that (i) each sublicensee shall expressly agree in writing to be bound by the terms and conditions of such direct license, and (ii) the obligations of Lilly under any such direct license shall be no greater than the obligations of
Lilly hereunder. 
 (b) Reversion of Patent Maintenance Responsibilities. Upon the effective date of the termination
of this Agreement, the sole responsibility for 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

29 

 
preparing, filing, prosecuting and maintaining the Licensed Patents will revert back to Lilly with no further notice or action required on Lilly’s behalf; provided, however, that if the
termination relates only to a specific country, then only the patent maintenance obligations pertaining to such country will revert to Lilly hereunder. In such case, CoLucid will maintain its patent responsibilities for all other Licensed
Patents. 
 (c) Non-Exclusive License and Access to CoLucid Technology. CoLucid will automatically grant to
Lilly a non-exclusive, world-wide, license, with the right to sublicense, under CoLucid Technology to make, have made, use, offer to sell, sell and import Product solely in the country or countries in which CoLucid’s rights to Product were so
terminated. The Parties shall negotiate in good faith reasonable compensation from Lilly to CoLucid for such license. Lilly shall have the right, but not the obligation, at its own expense, to take legal action against Third Person infringement of
CoLucid Technology licensed under this Section 11.3(c), and CoLucid consents to be a party and cooperate with Lilly in any such action brought by Lilly pursuant to this Section 11.3(c). Lilly will reimburse CoLucid for all documented
reasonable expenses incurred by CoLucid in connection with such cooperation. Further, no settlement, consent judgment or other final disposition of an action for infringement or validity may be entered into for any CoLucid Technology licensed under
this Section 11.3(c) without Lilly’s written consent, which consent shall not be unreasonably withheld, unless there is no finding or admission of either infringement by or non-validity of any patents under such CoLucid Technology.

 (d) Disposition of Inventory Upon Termination. CoLucid shall promptly transfer all quantities of any remaining
Compound supplied by Lilly to CoLucid. If Lilly terminates this Agreement after CoLucid has obtained a Regulatory Approval for the Product, CoLucid will promptly offer to sell to Lilly or its designee, at CoLucid’s actual cost (determined in
accordance with GAAP) plus a reasonable markup comparable to markups charged by contract manufacturers in the pharmaceutical manufacturing industry, CoLucid’s inventory of the Product existing on the date of termination
(“CoLucid Inventory”). CoLucid will be entitled to finish manufacturing any work-in-process into the Product, and such newly made Product will be considered CoLucid Inventory hereunder. If Lilly so requests,
CoLucid shall use its commercially reasonable efforts to continue manufacturing for Lilly for a period of time reasonably sufficient to permit Lilly to locate and qualify an alternative source of supply. If CoLucid is then utilizing third
party manufacturers, CoLucid will use its commercially reasonable efforts to cause such suppliers to provide supply to Lilly. If termination of this Agreement relates only to a specific country, the provisions of this Section 11.3(d) are
applicable only to CoLucid’s Product inventories for the country (as determined by CoLucid’s records) where such termination occurred; provided, however, that CoLucid may, at its option, promptly ship any inventory of Product in such
country to a country in which it retains the right to market and sell such Product. 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

30 

 (e) Transfer of Regulatory Documents. CoLucid shall immediately transfer
possession and ownership (and shall cause all contractors used by CoLucid to provide services hereunder to transfer possession and ownership) to Lilly (and in Lilly’s name where appropriate) of all Clinical Trial data and information, all
Clinical Trial databases, all data generated in support of Applications for Marketing Authorization, Regulatory Approvals or other regulatory commitments (e.g., toxicology and stability data) and regulatory documents (including,
but not limited to, Applications for Marketing Authorization, Regulatory Approvals and any correspondence between CoLucid and any sublicensee or contractor of CoLucid and any regulatory agency) that were created and/or developed under the terms of
this Agreement for Compound or Product (collectively, the “Regulatory Documents”); provided, however, that if the termination relates only to a specific country, then only the Regulatory Documents pertaining to
such country will be transferred to Lilly hereunder. In such case, CoLucid will maintain possession and ownership of all other Regulatory Documents. Should Lilly elect to sublicense, or to co-market or
co-promote Product with a Third Person in the Territory, pursuant to Lilly’s rights under this Section 11.3, Lilly shall have the right to provide appropriate access to such Clinical Trial data or
information, Clinical Trial databases, all data generated in support of any Application for Marketing Authorization, Regulatory Approval other regulatory commitment, or Regulatory Document to such Third Person. Except as contemplated by subsection
(c) above, CoLucid shall not be entitled to any compensation for the use of Regulatory Materials. 
 (f)
Assignment of Trademarks. CoLucid shall assign to Lilly its trademark rights for the Product, including, without limitation, any back-up marks, registrations, or applications for such marks and the goodwill associated with such marks; provided,
however, that if the termination relates only to a specific country, then only the trademark rights pertaining to such country will be transferred to Lilly hereunder. In such case, CoLucid will maintain possession and ownership of all other
trademarks. The parties shall negotiate in good faith reasonable compensation from Lilly to CoLucid for such trademark and goodwill. 

11.4 Termination by CoLucid. 

(a) If CoLucid reasonably believes, in light of the factors identified in the definition of Diligence in Article 1, that
it would be commercially unreasonable to continue to develop the Product as set forth in this Agreement, it may terminate this Agreement upon ninety (90) days written notice to Lilly. 

(b) Upon any material breach of this Agreement by Lilly, CoLucid may, at its option, terminate this Agreement upon
ninety (90) days written notice to Lilly. Such termination shall become effective at the end of such ninety (90) day period unless Lilly cures such breach or violation during such ninety (90) day period; provided, however, in the case
of a breach or violation that cannot be cured within such ninety (90) day period, CoLucid may terminate this Agreement following such ninety (90) day period only if Lilly shall have failed to commence

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

31 

 
substantial remedial actions within such ninety (90) day period and to use best efforts to pursue the same. 

(c) If CoLucid terminates this Agreement under Section 11.4(a), then the terms of Section 11.3 shall apply. If
CoLucid terminates this Agreement under Section 11.4(b), 11.5, or 12.3, then CoLucid shall retain any and all licenses granted to it by Lilly pursuant to Section 2.1 (unless otherwise terminated pursuant to the terms of this Agreement),
and CoLucid’s payment obligations under Article 3 and other relevant provisions shall continue in full force and effect, but CoLucid’s Diligence obligations under Sections 4.3, 4.4 and 4.5(a) will terminate. 

11.5 Termination for Bankruptcy. Notwithstanding any other provision of this Article 11, either Party may terminate this Agreement by
providing written notice to the other Party (with immediate effect) if the other Party: 
 (a) makes a general
assignment of substantially all of its assets for the benefit of creditors; 
 (b) petitions for or acquiesces in the
appointment of any receiver, trustee or similar officer to liquidate or conserve its business or all or substantially all of its assets; or 

(c) voluntarily commences under the laws of any jurisdiction any proceeding for relief under the Bankruptcy Code of
1986, as amended (“Code”) or similar bankruptcy laws in applicable jurisdictions, involving its insolvency, reorganization, adjustment of debt, dissolution, liquidation or any other similar proceeding for the release of
financially distressed debtors. 
 11.6 Change in CoLucid’s Ownership. If CoLucid undergoes a Change of Control, CoLucid will
promptly notify Lilly in writing thereof and Lilly may terminate this Agreement by providing written notice to CoLucid and such termination shall become effective upon CoLucid’s receipt of such notice unless the new controlling Third Person
agrees in writing to be bound by the terms and conditions of this Agreement and to undertake all of CoLucid’s obligations under this Agreement. 

11.7 Residual Obligation Upon Termination. Termination of this Agreement for any reason will not relieve either Party of any obligation
or liability accruing prior thereto and will be without prejudice to the rights and remedies of either Party with respect to any antecedent breach of the provisions of this Agreement. Without limiting the generality of the foregoing and in addition
to the foregoing and the rights upon termination set forth in Sections 11.2 and 11.4, no termination of this Agreement, whether by lapse of time or otherwise, will serve to terminate the rights and obligations of the Parties hereto with respect
to this Agreement as it relates to the jurisdiction(s) for which this Agreement has not been terminated. The provisions of Article 1, Section 6.6, Article 7, Sections 8.7 and 8.8, Article 9, Article 10, Section 11.3, 11.7, 11.8, 11.9 and

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

32 

 
Article 12 are intended to and shall survive termination or expiration of this Agreement in accordance with the terms of such Articles or Sections. 

11.8 Additional Remedies. The remedies set forth in this Article 11 or elsewhere in this Agreement will be in addition to, and will not
be to the exclusion of, any other remedies available to the Parties at law, in equity or under this Agreement. 
 11.9 Further
Assurances. CoLucid covenants and agrees that if this Agreement is terminated under Sections 11.2, 11.5 or 12.3, and if any Regulatory Document(s) described in Section 11.3(d) or any trademark described in Section 11.3(e) cannot
be transferred or assigned under Applicable Law, or is untransferable by its nature, then CoLucid will cause the beneficial interest in and to the same, in any event, to pass to Lilly, and CoLucid, covenants and agrees, after such termination to
hold such Regulatory Document(s) and trademark(s) in trust for, and for the benefit of Lilly; provided, all payments owed to CoLucid under this Agreement have been paid by Lilly. 

ARTICLE 12 

MISCELLANEOUS 
 12.1
Independent Contractor. It is understood and agreed that the Parties shall have the status of an independent contractor under this Agreement and that nothing in this Agreement shall be construed as creating any partnership, joint venture or
employer-employee relationship between the Parties or as authorization for either CoLucid or Lilly to act as agent for the other. 
 12.2
No Benefit to Others. The representations, warranties, covenants and agreements contained in this Agreement are for the sole benefit of the Parties and their legal representatives, successors and assigns, and they shall not be construed as
conferring any rights to any Third Person. 
 12.3 Force Majeure. If either Party is affected by any extraordinary, unexpected and
unavoidable event such as acts of God, floods, fires, riots, war, labor disturbances, failures of sources of supply, infectious diseases of animals, or by the reason of any law, order, proclamation, regulation, ordinance, demand or requirement of
the relevant government or any authority or representative thereof, or by reason of any other cause whatsoever (provided that in all such cases the Party claiming relief on account of such event can demonstrate that such event was extraordinary,
unexpected and unavoidable by the exercise of reasonable care) (“Force Majeure”) it shall notify the other Party within five (5) business days of the nature and extent thereof and take all reasonable steps to overcome
the Force Majeure and to minimize the loss occasioned to that other Party. Such notice will be provided within five (5) business days of the occurrence of such event and will identify the requirements of this Agreement or such of its
obligations as may be affected, and, subject to the provisions below, to the extent so affected, said obligations will be suspended during the period of such disability. The Party prevented from performing hereunder will use reasonable efforts to
remove such disability and will continue performance whenever such causes are removed. The Party 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

33 

 
so affected will give to the other Party a good faith estimate of the continuing effect of the Force Majeure condition and the duration of the affected Party’s nonperformance. 

If the period of any previous actual nonperformance of Lilly because of Lilly Force Majeure conditions plus the anticipated future period of
Lilly nonperformance because of such conditions will exceed an aggregate of one hundred eighty (180) consecutive days within any one year period, CoLucid may terminate this Agreement immediately by written notice to Lilly. 

If the period of any previous actual nonperformance of CoLucid because of CoLucid Force Majeure conditions will exceed one hundred eighty
(180) consecutive days, Lilly may terminate this Agreement immediately by written notice to CoLucid; provided, however, that to the extent such nonperformance by CoLucid affects CoLucid’s performance and Lilly’s rights under this
Agreement as it relates to one or more countries, but not all countries, Lilly may terminate this Agreement after such one hundred eighty (180) day period as to the affected country or countries only, and in such case this Agreement will remain
in full force and effect with respect to the countries that are not terminated. 
 Notwithstanding the foregoing, when such circumstances as
those contemplated herein arise, the Parties will discuss in good faith, what, if any, modification of the terms set forth herein may be required in order to arrive at an equitable solution. 

12.4 Amendment. This Agreement may not be amended, supplemented, or otherwise modified except by an instrument in writing signed by
authorized representatives of the Parties. 
 12.5 Entire Agreement. This Agreement constitutes the entire agreement and
understanding relating to the subject matter of this Agreement and supersedes all previous communications, proposals, representations and agreements, whether oral or written, relating to the subject matter of this Agreement, including the
Confidentiality and Non-Use Agreement dated September 21, 2004, the Original Agreement and the Prior Amendments. 

12.6 Severability. If any provision of this Agreement is held to be illegal, invalid, or unenforceable under present or future laws
effective while this Agreement remains in effect, the legality, validity and enforceability of the remaining provisions will not be affected thereby. 

12.7 Waiver. Any term or provision of this Agreement may be waived at any time by the Party entitled to the benefit thereof only by a
written instrument executed by such Party. No delay on the part of Lilly or CoLucid in exercising any right, power or privilege hereunder will operate as a waiver thereof, nor will any waiver on the part of either Lilly or CoLucid of any right,
power or privilege hereunder operate as a waiver of any other right, power or privilege hereunder nor will any single or partial exercise of any right, power or privilege hereunder preclude any other or further exercise thereof or the exercise of
any other right, power or privilege hereunder. 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

34 

 12.8 Notices. All notices required or permitted to be given under this Agreement shall be
in writing and shall be deemed given upon receipt if delivered personally or by facsimile transmission (receipt verified), telexed, mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by prepaid express
courier service, to the Parties at the following addresses (or at such other address for a Party as shall be specified by the notice; provided, that notices of a change of address shall be effective only upon receipt thereof): 

 

			
	For CoLucid:		CoLucid Pharmaceuticals, Inc.
			P.O. Box 425227
			Cambridge, Massachusetts 02142
			Attention: Chief Executive Officer
		
	With a copy to:		  
 Faegre Baker Daniels LLP

600 East 96th St.; Suite 600

Indianapolis, Indiana 46240
 Attention: Daniel L. Boeglin

Fax: 317-569-4800

		
	For Lilly:		 Eli Lilly and Company
 Lilly Corporate
Center
 Indianapolis, Indiana 46285
 United States of
America
 Attention: General Counsel
 Fax: 317-276-9152

		
	With a copy to:		  
 Eli Lilly and Company

Lilly Corporate Center
 Indianapolis, Indiana 46285

United States of America
 Attention: Vice President, LRL
Neuroscience

 12.9 Governing Law. This Agreement shall be governed by, and construed in accordance with, the
laws of the State of Indiana, United States, excluding any choice of law rules, which may direct the application of the law of any other jurisdiction. However, the scope, validity and enforceability of any patents encompassed within the scope of
this Agreement shall be determined in accordance with the applicable laws of the countries in which such patents have issued. 
 12.10
Assignability. During the term of this Agreement, neither Party shall assign any benefit or burden under this Agreement without prior written consent of the other Party, which shall not be unreasonably withheld, except that (i) either Party
may assign its rights and obligations under this Agreement to an Affiliate or to any company with which it may merge or consolidate or to any company to whom it may transfer substantially all of its assets or to any company which may acquire such
Party (including, 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

35 

 
in each case, any company created as a new vehicle upon any such merger, transfer or acquisition), (ii) CoLucid may transfer any and all of its rights to a sublicensee as provided by this
Agreement and (iii) Lilly may freely assign its royalty interest in whole or in part. This Agreement shall be binding on and inure to the benefit of the parties hereto and their respective permitted successors and assigns. 

12.11 Jointly Prepared. This Agreement will be deemed to have been drafted by both Lilly and CoLucid and will not be construed against
either Party as the draftsperson hereof. 
 12.12 Headings, Gender and Number. All section and article titles or captions contained
in this Agreement and in any exhibit, schedule or certificate referred to herein or annexed to this Agreement are for convenience only, will not be deemed a part of this Agreement and will not affect the meaning or interpretation of this Agreement.
Words used herein, regardless of the number and gender specifically used, shall be deemed and construed to include any other number, singular or plural, and other gender, masculine, feminine, or neuter, as the context requires. 

12.13 Dispute Resolution. If any dispute arises relating to this Agreement, prior to instituting any lawsuit or other dispute
resolution process on account of such dispute, the Parties will attempt in good faith to settle such dispute first by negotiation and consultation between themselves, including referral of such dispute to the Chief Executive Officer of CoLucid and
the Vice President, LRL Neuroscience, of Lilly. If such executives are unable to resolve such dispute or agree upon a mechanism to resolve such dispute within sixty (60) days of the first written request for dispute resolution under this
Section 12.13, then at the request of either Party the dispute shall be submitted to non-binding mediation before a mutually acceptable mediator chosen by agreement of the parties. This provision shall not preclude any Party from seeking
immediate injunctive relief in the event such Party believes that irreparable harm will occur. 
 12.14 Counterparts. This Agreement
may be executed in one or more counterparts, each of which shall be an original, but all of which taken together shall constitute one and the same agreement. It shall not be necessary in making proof of this Agreement or any counterpart hereof to
produce or account for any of the other counterparts. 
 12.15 Schedules, Exhibits and Attachments. All schedules, exhibits and
attachments (including, without limitation, the Development Plan) referred to herein are intended to be and hereby are specifically made part of this Agreement. However, if there is a conflict between a term or condition of such schedules, exhibits
and attachments and this Agreement, the terms and conditions of this Agreement shall prevail. 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

36 

 12.16 Further Assurances. At any time during the term of this Agreement, Lilly and CoLucid
each will, at the request of the other Party, use reasonable efforts to (a) deliver to the other Party such records, data or other documents, consistent with the provisions of this Agreement, (b) execute, deliver or cause to be delivered,
all such assignments, consents, documents or further instruments of transfer or license, and (c) take or cause to be taken all such other actions, as a Party reasonably may deem necessary or desirable in order for such Party to obtain the full
benefits of this Agreement and the transactions contemplated hereby. 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

37 

 IN WITNESS WHEREOF, the Parties by their
respective authorized representatives, have executed this Agreement. 
  

			
	ELI LILLY AND COMPANY
		
	By:		 /s/ Darren J. Carroll

	Printed:		Darren J. Carroll
	Title:		SVP Corporate Bus. Dev.
	
	COLUCID PHARMACEUTICALS, INC.
		
	By:		 /s/ Thomas P. Mathers

	Printed:		Thomas P. Mathers
	Title:		CEO

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

38 

 EXHIBIT A 

Licensed Patents 
 LY573144 

 

																	
	 Docket No.
	 	 Country
	 	 Status
	 	 Substatus
	 	 Application Number
	 	 Ap. Date
	 	 Patent Number
	 	 Grant Date
	 	 Expiration Date

	X14075	 	Algeria	 	Filed	 	Filed	 	40257	 	27-Mar-03	 		 		 	
	X14075	 	Argentina	 	Filed	 	Filed	 	P030101055	 	5-Mar-03	 		 		 	
	X14075	 	Australia	 	Filed	 	Filed	 	2003224719	 	27-Mar-03	 		 		 	
	X14075	 	Brazil	 	Filed	 	Filed	 	PI0308495-7	 	27-Mar-03	 		 		 	
	X14075	 	Canada	 	Filed	 	Filed	 	2478229	 	27-Mar-03	 		 		 	
	X14075	 	Chile	 	Filed	 	Filed	 	612-2003	 	26-Mar-03	 		 		 	
	X14075	 	China P.R.	 	Filed	 	Filed	 	3807363.3	 	27-Mar-03	 		 		 	
	X14075	 	Colombia	 	Filed	 	Filed	 	4096137	 	27-Mar-03	 		 		 	
	X14075	 	Costa Rica	 	Filed	 	Filed	 	7496	 	27-Mar-03	 		 		 	
	X14075	 	Croatia	 	Filed	 	Published	 	P20040883 A	 	27-Mar-03	 		 		 	
	X14075	 	Ecuador	 	Filed	 	Filed	 	04-5317-PCT	 	27-Mar-03	 		 		 	
	X14075	 	El Salvador	 	Filed	 	Filed	 	E-1691-2003	 	5-Mar-03	 		 		 	
	X14075	 	Eurasian Patent Convention	 	Filed	 	Filed	 	200401282	 	27-Mar-03	 		 		 	
	X14075	 	European Patent Convention	 	Filed	 	Published	 	3721402	 	27-Mar-03	 		 		 	
	X14075	 	Hong Kong	 	Docketed	 	Mailed	 	PCT/US03/08455	 		 		 		 	
	X14075	 	Indonesia	 	Filed	 	Filed	 	W-00200402114	 	27-Mar-03	 		 		 	
	X14075	 	Israel	 	Filed	 	Filed	 	163928	 	27-Mar-03	 		 		 	
	X14075	 	Japan	 	Filed	 	Filed	 	2003-582146	 	27-Mar-03	 		 		 	
	X14075	 	Korea South	 	Filed	 	Published	 	10-2004-7015294	 	27-Mar-03	 		 		 	
	X14075	 	Malaysia	 	Filed	 	Filed	 	PI20031097	 	5-Mar-03	 		 		 	
	X14075	 	Mexico	 	Filed	 	Filed	 	PA/A/2004/009497	 	27-Mar-03	 		 		 	
	X14075	 	New Zealand	 	Filed	 	Filed	 	534952	 	27-Mar-03	 		 		 	
	X14075	 	Nigeria	 	Granted	 	Granted	 	123/2003	 	12-Mar-03	 	RP15220	 	29-Oct-03	 	12-Mar-23
	X14075	 	Norway	 	Filed	 	Filed	 	20044654	 	27-Mar-03	 		 		 	
	X14075	 	Patent Cooperation Treaty	 	Inactive	 	National	 	PCT/US03/08455	 	27-Mar-03	 		 		 	
	X14075	 	Peru	 	Filed	 	Published	 	301	 	5-Mar-03	 		 		 	
	X14075	 	Philippines	 	Filed	 	Published	 	1-2004-501520	 	27-Mar-03	 		 		 	
	X14075	 	Poland	 	Filed	 	Filed	 	P-372845	 	27-Mar-03	 		 		 	
	X14075	 	Singapore	 	Filed	 	Filed	 	200405216-3	 	27-Mar-03	 		 		 	
	X14075	 	South Africa	 	Filed	 	Filed	 	2004/7666	 	27-Mar-03	 		 		 	
	X14075	 	Taiwan	 	Filed	 	Published	 	92106334	 	21-Mar-03	 		 		 	
	X14075	 	Thailand	 	Filed	 	Published	 	81304	 	5-Mar-03	 		 		 	
	X14075	 	Ukraine	 	Filed	 	Filed	 	20040907833	 	27-Mar-03	 		 		 	
	X14075	 	United States	 	Filed	 	Filed	 	10/509770	 	27-Mar-03	 		 		 	
	X14075	 	Venezuela	 	Filed	 	Filed	 	2003-000468	 	26-Mar-03	 		 		 	
	X14075	 	Vietnam	 	Inactive	 	Abandoned	 	1-2004-00976	 	27-Mar-03	 		 		 	
	X14075T	 	Egypt	 	Filed	 	Filed	 	289/2003	 	5-Mar-03	 		 		 	
	X14075T	 	India	 	Filed	 	Filed	 	01392/KOL/NP/04	 	27-Mar-03	 		 		 	
	X14075T	 	Pakistan	 	Filed	 	Filed	 	237/2003	 	20-Mar-03	 		 		 	

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

39 

 EXHIBIT B 

Compound Supply 
 API 

All API is transferred AS IS and CoLucid shall be solely responsible for determining its suitability for developmental or clinical trial use.

 2.5 kg LY573144 hemisuccinate manufactured and located at MSG (Belgium). 

 

	 	•	 	Material is past its re-evaluation date. 

  

	 	•	 	Material may not in any event be used for pivotal clinical trials. 

 An additional 800 g is
available that may be suitable for development use only (two lots: 200 g and 600 g), but shall not in any circumstances be used in humans. 
  

	 	•	 	Reference standard is available, but will need re-evaluation by CoLucid before use. This material was not made using cGMP. 

Analytical Methods 
 Analytical methods
have been developed and will be supplied, but not transferred. Validation will be required by CoLucid’s analytical lab prior to use. 
 Drug Product

 All Drug Product is transferred AS IS and CoLucid shall be solely responsible for determining its suitability for developmental or
clinical trial use. 
 400 unlabeled vials of the 3mg/ml CT material are available. 

 

	 	•	 	Material is past expiry dating. 

  

	 	•	 	Stability samples that may be useful to extend dating are still in stability chambers at a 3rd party and will remain until Jun-06. 

Since material was imported “Import for Export”, shipment of the material needs to comply with FD&C Act 801(d)(3). 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

40 

 EXHIBIT C 

Near Term Migraine Product Development Plan 
 Product
assumptions 
 Non-triptan, but similar efficacy. May need to prove absence of human coronary vasoconstriction with comparison to triptan for marketing.

 Potential efficacy as prophylactic migraine drug and preventive agent given at onset of aura or during prodrome. This will not be part of this proposed
development plan. 
 Need to demonstrate that nausea, vomiting, phonophobia, photophobia are improved. FDA considers pain improvement in the absence of
improvements in other features to be inadequate. 
 Can be administered IV, sublingual, or oral. 

Might have efficacy in delayed emesis. 
 Development Plan

 Migraine 
 Phase 1 studies for a new agent are
shown in Table 1. Given the thorough toxicology package that has been performed on the molecule, it is not thought that extensive additional studies will need to be performed prior to Phase 1 studies with a sublingual formulation. Preparation of a
new formulation will require an animal study to demonstrate lack of irritability of the administration and the absorption of the drug substance. Preparation of study drug is not included in the cost estimates. The Phase 1 study could potentially
compare the sublingual formulation to oral or iv doses. Assuming the data from the study is clean, Phase 2 could proceed. There is a possibility that additional studies will be required to examine any cardiac issues. For marketing reasons, these
might be helpful. 
 Phase 2 studies for acute migraine (moderate to severe) are shown in Table 2. The Phase 2 study would include an initial study to
determine the maximum tolerated dose and the second study would be a proof-of-concept study. A multiple dose study is also planned. 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

41 

 Delayed Emesis 

Since delayed emesis will be submitted to a different division, it is likely that that division would request a full ICH exposure in that indication. This
could be discussed and a smaller exposure might be negotiated. 
 The Phase 2 studies for delayed emesis are shown in Table 3. 

Fastest Route to Efficacy Study in Migraine 
 Given that
animals have been dosed in a regulatory 2 week intravenous study defining a NOAEL dose and that an intravenous study has been done in subjects defining the PK in man and that the dosage form planned for use in man is sublingual (or oral), the first
clinical pharmacology study will be single dose escalation to find the maximal tolerated dose in man. There would be a minimum of two groups of 8 subjects, each dosed at two dosage levels. The kinetics of the sublingual dosing should be compared to
the IV dosing as the study progresses to help define the maximal tolerated dose. You will notice in the table below that there are additional arms of the study, which would likely be beneficial. If the clinical trials use multiple dosing, a multiple
dose clinical pharmacology trial will be required to demonstrate pharmacokinetics and safety at steady state. 
 The POC clinical study would be in moderate
to severe acute migraine which will use a single dose. Patients who meet the study criteria are given blinded study drug to take with their next moderate or severe migraine headache. They subsequently complete a diary recording the severity of their
symptoms at defined times over the next several hours. This study would use study drug at the maximum tolerated dose and placebo. Efficacy in this trial would be sufficient to move forward. 

Fastest Route to Efficacy Study in Delayed Emesis 
 This
study will require toxicology support for at least 2 weeks. In addition, to the single dose preclinical pharmacology trial, a clinical pharmacology study in subjects dosed to maximum tolerated efficacy dose in steady state will be needed. An
efficacy study requiring up to 1 week of dosing should be sufficient for a proof of concept trial. 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

42 

 Table 1. Projected Clinical Phase 1 Plan for Registration 

 

							
	 Study/Objective
	  	 Design
	  	 Duration
	  	N
	Absolute bioavailability	  	Crossover IV versus sublingual or oral, kinetics	  	Single dose	  	16
				
	Multiple dose	  	Parallel, include QTc evaluation, steady state kinetics	  	1 week	  	24
				
		  	** Studies could potentially be combined into one multiple dose study looking at kinetics	  		  	
				
	Subtotal:	  		  		  	
				
	Drug interaction studies (several of these depending upon characteristics of drug)	  	“Crossover”, These would include analgesics, prophylaxis agents, chemotherapeutic agents, etc. that will be used concomitantly with this formulation	  	Single dose?	  	24
				
		  	** This study of drug interaction will likely have to be performed.	  		  	
				
	Subtotal:	  		  		  	
				
	QTc trial in migraineurs	  	Cross-over, dose response, efficacy	  	Multiple single doses	  	160
				
	Cardiac catheterization for CA constriction (absence)	  	Parallel, dose response, placebo-controlled, include QTc – this should only be performed after consultation with the FDA on the ability to get a differentiating label	  	Single dose	  	48
				
		  	** These studies may be required depending on how the cardiac evaluation looks in the first two studies above. Based on the Phase 1 conducted and the clean Dog CV study, this should not be the case.	  		  	

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

1 

 Table 2. Phase 2 Clinical Plan for Migraine 

 

									
	 Phase / Indication
	  	 Study/Objective
	  	 Design
	  	 Duration
	  	 Number of
patients

	Phase 2 / Moderate/severe migraine HA pain #1	  	Dose response efficacy study (3 doses: X, 2X, & 4X) and Safety	  	Parallel, placebo controlled, include QTc evaluation	  	Single migraine, consider follow-up data to confirm safety.	  	4 X 60 = 240
					
	Phase 2 / Moderate/severe migraine HA pain #2	  	Dose response efficacy study (use best dose from study #1 and up to 4 other doses) and Safety	  	Parallel, placebo controlled, include QTc evaluation	  	Single migraine, consider follow-up data to confirm safety.	  	5 X 60 = 300
					
	Phase 2 / Repeated dose migraine study	  	Efficacy and safety	  	Parallel, comparator and placebo controlled. Consider imbalance (2:1:1). Second dose in nonresponders.	  	 Single HA
 Alternatively could treat 2-3
migraines.
	  	4 X 100 = 400

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

2 

 Table 3. Phase 1B/2 Studies for Delayed Emesis indication Submission without a migraine package 

 

									
	 Phase / Indication
	 	 Study/Objective
	 	 Design
	 	Duration	  	 Number of

patients

	Phase 1B / Proof of concept	 	Stand alone	 	Parallel, MTD vs. placebo	 	1-2 weeks	  	2 X 50 = 100
					
	Phase 1B / Proof of concept	 	Add-on to standard therapy	 	Parallel, MTD vs. placebo	 	1-2 weeks	  	2 X 50 = 100
					
	Phase 2 / Dose response a	 	Efficacy	 	Parallel, 3 doses vs. placebo	 	1-2 weeks	  	4 X 100 = 400
					
	Phase 2 / Dose response a	 	 Efficacy/Add on to

standard therapy
	 	Parallel, 3 doses vs. placebo	 	1-2 weeks	  	4 X 100 = 400

 This plan assumes that the dosage will be similar to that of migraine and that the FDA will accept safety data in migraine to
permit a reduced number of exposures. 

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

3 

 EXHIBIT D 

KNOW-HOW 
  

					
	 ADME
	  	 	  	 
	1	  	LY573144 ADME Summary Slides.ppt	  	ADME Summary Slides
			
	2	  	LY573144 011D03 EX.doc	  	Elimination of Radioactivity from Female Beagle Dogs Following Either a Single Intravenous Dose or a Single Oral Dose of 6 mg/kg [14C]LY573144 as the Hemisuccinate
			
	3	  	ID	  	File Name
			
	4	  	LY573144 ADME 011D03 PK.doc	  	Plasma Pharmacokinetics of Radioactivity and LY573144 and Red Blood Cell Distribution in Female Beagle Dogs Following a Single Intravenous or Oral Dose of 6 mg/kg of [14C]LY573144 as the Hemisuccinate
			
	5	  	LY573144 ADME C14 SYN Rpt.doc	  	Synthesis of 2,4,6-Trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl-[2,6-14C2]]benzamide Hemisuccinate, LY573144-[14C2] Hemisuccinate
			
	6	  	LY573144 ADME Rpt 011D03 Metab.doc	  	Metabolism of LY573144 in Female Beagle Dogs Following a Single Intravenous or a Single Oral Dose of 6 mg/kg [14C]LY573144·Hemisuccinate
			
	7	  	LY573144 ADME Rpt 02.doc	  	In Vitro Metabolism of LY573144 Studied in Liver Microsomes and Cryopreserved Hepatocytes from Human, Rat, Dog, and Monkey, and In Vivo Metabolism Studied in Plasma from Rat, Dog, and Monkey and in Urine from Rat and
Dog
			
	8	  	LY573144 ADME Rpt 03.doc	  	Plasma Toxicokinetics of LY573144 in Fischer 344 Rats Following Intravenous Infusion of 4, 12, or 40 mg/kg/day LY573144 Hemisuccinate for 14 Days
			
	9	  	LY573144 ADME Rpt 04.doc	  	Toxicokinetics of LY573144 in Beagle Dogs Following a Single Intravenous Infusion of 2, 6, or 15 mg LY573144 Hemisuccinate/kg for 14 Days
			
	10	  	LY573144 ADME Rpt 05.doc	  	Drug Effects on Hepatic Microsomal Drug Metabolizing Enzymes in Beagle Dogs Given LY573144 Hemisuccinate by Intravenous Infusion for 2 Weeks
			
	11	  	LY573144 ADME Rpt 06.doc	  	Toxicokinetics of LY573144 in Gravid New Zealand White Rabbits Following a Single Intravenous Infusion of 5, 10, or 20 mg/kg LY573144 Hemisuccinate on Day 11 of Gestation
			
	12	  	LY573144 ADME Rpt 07.doc	  	Toxicokinetics of LY573144 in Gravid New Zealand White Rabbits Following a Single Intravenous Infusion of 5, 10, or 20 mg/kg LY573144 Hemisuccinate on Day 11 of Gestation
			
	13	  	LY573144 ADME Rpt 08.doc	  	Plasma Toxicokinetics of LY573144 in Gravid CD Rats on Day 12 of Gestation Following Daily Intravenous Infusions of 5, 15, or 75 mg/kg LY573144 as the Hemisuccinate Salt on Gestation Days 6 through 12
			
	14	  	LY573144 ADME Rpt 09.doc	  	In Vitro Interaction of LY573144 with Human Cytochromes P450 CYP3A, CYP2D6, CYP2C19, CYP2C9, and CYP1A2

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

1 

					
			
	15		LY573144 ADME Rpt 10.doc		Synthesis of 2,4,6-Trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl-[2,6-14C2]]benzamide Hemisuccinate, LY573144-[14C2] Hemisuccinate

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

2 

					
	 ID

Toxicology
	  	 File Name
	  	 Document Title

	1	  	LY573144 Toxicology Summary Slides.ppt	  	Toxicology Summary Slides
			
	2	  	Genpharm01 Receptor.pdf	  	Receptor Pharmacology Study of LY517717 Difumarate Using Radiolabeled Receptor Binding and Isolated Tissue-Bath Preparations
			
	3	  	Genpharm02 HERG.pdf	  	Human Cardiac IKr (HERG) Blocking Profile of Compound 517717 Hydrochloride
			
	4	  	Genpharm03 respiratory.pdf	  	Effect of Single-Dose Oral Administration of LY517717 Difumarate on Respiratory Patterns of Male Rats
			
	5	  	Genpharm04 CNS.pdf	  	CNS/Behavioral Effects of Single-Dose Oral Administration of LY517717 Difumarate in Male CD-1 Mice
			
	6	  	Genpharm05 CV.pdf	  	Telemetry Cardiovascular Assessment Study in Conscious Rats of Orally Administered Compound LY517717 Difumarate
			
	7	  	Genpharm06 hemolysis.pdf	  	Hemolytic Potential and Blood Compatibility Testing with LY573144 Hemisuccinate
			
	8	  	Tox01 single_dose.pdf	  	A Single-Dose Toxicity Study in Fischer 344 Rats Given LY573144 Hemisuccinate Intravenously
			
	9	  	Tox02 in vitro ocular.pdf	  	Bovine Corneal Opacity And Permeability Assay LY573144 Hemisuccinate (Compound 683974) Final Report
			
	10	  	Tox03 Micronucleus.pdf	  	The Effect of LY573144 Hemisuccinate Given Intravenously for 2 Consecutive Days on the Induction of Micronuclei in Bone Marrow of ICR Mice
			
	11	  	Tox04 Chrom Ab.pdf	  	The Effect of LY573144 Hemisuccinate on the In Vitro Induction of Chromosome Aberrations in Chinese Hamster Ovary Cells
			
	12	  	Tox05 Ames.pdf	  	The Effect of LY573144 Hemisuccinate on the Induction of Reverse Mutations in Salmonella typhimurium and Escherichia coli Using the Ames Test
			
	13	  	Tox06 Repeat_dose rat.pdf	  	A 2-Week Intravenous Infusion Toxicity Study of LY573144 Hemisuccinate (Compound 683974) in the Fischer 344 Rat
			
	14	  	Tox08 Repeat_dose Dog.pdf	  	A 2-Week Intravenous Infusion Toxicity Study of LY573144 Hemisuccinate in the Beagle Dog
			
	15	  	Tox09 embryofetal rat.pdf	  	An Embryo-Fetal Development Study of LY573144 Hemisuccinate (Compound 683974) Administered by Intravenous Infusion in the Rat and Companion Blood Level Study
			
	16	  	Tox10 embryofetal rabbit.pdf	  	An Embryo-Fetal Development (Segment II) Study of LY573144 Hemisuccinate (Compound 683974) Administered Intravenously in the New Zealand White Rabbit

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

3 

					
	 ID

Discovery
	  	 File Name
	  	 Document Title

	1	  	LY573144 Discovery Summary Slides	  	Discovery Summary Slides
			
	2	  	5HT1F_Candidate Selection Document	  	Candidate Selection Document—Description of all Preclinical Work

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

4 

					
	 ID

Clinical
	  	 File Name
	  	 Document Title

	1	  	LY573144 Clinical Summary Slides.ppt	  	Clinical Summary Slides
			
	2	  	5HT1F CIB.pdf	  	Current CIB
			
	3	  	frLACA 27_05_04.doc	  	Phase 1 Clinical Study LACA Final Study Report

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

5 

					
	 ID

CMC
	  	 File Name
	  	 Document Title

	1	  	LY573144 CMC Summary Slides.ppt	  	CMC Summary Slides
			
	2	  	Summation of Analytical Methods and Reports.pdf	  	Summary Index of Hard Copy Files
			
	 Analytical
Methods
	  	 	  	 
	1	  	B09352_1.pdf	  	HPLC DETERMINATION OF LY573144 IN TOXICOLOGY FORMULATIONS
			
	2	  	B09626_1.pdf	  	HPLC DETERMINATION OF LY573144 FROM TEXWIPE SWABS
			
	3	  	B09979_1.pdf	  	HPLC DETERMINATION OF LY573144 FROM TEXWIPE SWABS
			
	4	  	TR16JUL2003RZ38451A.pdf	  	Validation Protocol For Method B09979, HPLC Determination of LY573144 on Cleaning Swabs
			
	 API
	  	 	  	 
	1	  	GMP Campaign 1 development report.pdf	  	GMP Campaign 1 : development report.
			
	2	  	LY573144 hemisuccinate analytical methods and unofficial results.pdf	  	LY573144 Hemisuccinate (683974). Analytical methods and non-official results.
			
	3	  	Optimisation and robustness study on last step.pdf	  	Optimisation and robustness study on the last step of synthesis of 5-HT1f 3rd gen candidate : M026-A13
			
	4	  	Pilot plant campaign 1 production report.pdf	  	LY683974 (M026-A13 0.5 SUC) Pilot Plant campaign 1 Production report
			
	5	  	TR11OCT2002YA00275A.pdf	  	Biopharmaceutical Properties for Program 5HT1f 3rd Generation
			
	6	  	TR25MAR2002YA00275A.pdf	  	Biopharmaceutical Properties and Salt Selection for Program 5HT1f 3rd Generation
			
	 Formulation
	  	 	  	 
	1	  	TR04FEB2004RZ38452A.PDF	  	LY573144 Formulation Development Report I: Parenteral Solution Formulation, 1mg/ml, for First Human Dose Studies
			
	2	  	TR10JUN2004RZ38452A.PDF	  	LY573144 Formulation Development Report III: Parenteral Solution Formulation, 3mg/ml, for First Human Dose Studies
			
	3	  	TR10Jun2004RZ38452B.PDF	  	LY573144 Formulation Development Report II: Drug and Excipient Compatibility Study
			
	4	  	TR10NOV2003RZ38452B.PDF	  	Prediction of Bitter Taste of LY573144 Using a Rat Behavioral Taste Model
			
	5	  	TR14SEP2004RZ38452A.PDF	  	LY573144 Formulation Development Report IV: Prototype Sublingual Tablet Formulation Development and In Vivo Absorption in Dogs
			
	6	  	TR31JUL2002RZ38452A.PDF	  	Microbial Challenge Testing of LY573144 Hemisuccinate Salt (LY683974) solution for injection

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

6 

					
	 Specifications
	  	 	  	 
	1	  	specs for 3 mg per ml DP.pdf	  	Specification approval for 3 mg/ml drug product
			
	2	  	specs for API and 1 mg per ml DP.pdf	  	Specification approval for API and 1 mg/kg drug product

  
 CONFIDENTIAL TREATMENT REQUESTED

 [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 406 of the Securities Act of 1933, as amended, and Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

7EX-10.1

 Exhibit 10.1 

TAX MATTERS AGREEMENT 

BY AND BETWEEN 

JDS UNIPHASE CORPORATION 

AND 

LUMENTUM HOLDINGS INC. 

[—], 2015 

 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	 ARTICLE I
	  	DEFINITIONS	  	 	2	  
	 1.1
	  	Certain Definitions	  	 	2	  
	 1.2
	  	Other Terms	  	 	7	  
	 ARTICLE II
	  	PREPARATION AND FILING OF TAX RETURNS	  	 	7	  
	 2.1
	  	DSU’s Responsibility	  	 	7	  
	 2.2
	  	Holdings’ Responsibility	  	 	8	  
	 2.3
	  	Agent	  	 	8	  
	 2.4
	  	Manner of Tax Return Preparation	  	 	8	  
	 ARTICLE III
	  	LIABILITY FOR ORDINARY COURSE TAXES	  	 	8	  
	 3.1
	  	JDSU’s Liability for Ordinary Course Taxes and Contribution	  	 	8	  
	 3.2
	  	Holdings’ Liability for Ordinary Course Taxes	  	 	9	  
	 3.3
	  	Straddle Periods	  	 	9	  
	 3.4
	  	Refunds	  	 	9	  
	 3.5
	  	Payment of Tax Liability	  	 	9	  
	 3.6
	  	Computation	  	 	9	  
	 ARTICLE IV
	  	SEPARATION TAXES, TRANSFER TAXES, TAX ITEMS AND TAX ASSETS	  	 	10	  
	 4.1
	  	Separation Taxes	  	 	10	  
	 4.2
	  	Continuing Covenants	  	 	10	  
	 4.3
	  	Transfer Taxes	  	 	12	  
	 4.4
	  	Allocation of Tax Items	  	 	12	  
	 4.5
	  	Allocation of Tax Assets	  	 	12	  
	 ARTICLE V
	  	EMPLOYEE WAGES	  	 	12	  
	 ARTICLE VI
	  	INDEMNIFICATION	  	 	12	  
	 6.1
	  	In General	  	 	12	  
	 6.2
	  	Inaccurate or Incomplete Information	  	 	13	  
	 6.3
	  	No Indemnification for Tax Items	  	 	13	  
	 ARTICLE VII
	  	PAYMENTS	  	 	13	  
	 7.1
	  	Estimated Tax Payments	  	 	13	  
	 7.2
	  	True-Up Payments	  	 	13	  
	 7.3
	  	Redetermination Amounts	  	 	13	  
	 7.4
	  	Payments of Refunds and Credits	  	 	14	  
	 7.5
	  	Payments Under This Agreement	  	 	14	  
	 ARTICLE VIII
	  	TAX PROCEEDINGS	  	 	15	  
	 8.1
	  	In General	  	 	15	  
	 8.2
	  	Participation of non-Filing Party	  	 	15	  

  
 i 

 TABLE OF CONTENTS 

(continued) 
  

							
	 	 	 	  	Page	 
	 8.3
	 	Notice	  	 	15	  
	 8.4
	 	Control of Separation Tax Proceedings	  	 	15	  
	 ARTICLE IX
	 	MISCELLANEOUS PROVISIONS	  	 	15	  
	 9.1
	 	Corporate Power; Facsimile Signatures	  	 	15	  
	 9.2
	 	Cooperation and Separation of Information	  	 	16	  
	 9.3
	 	Dispute Resolution	  	 	17	  
	 9.4
	 	Confidentiality	  	 	18	  
	 9.5
	 	Setoff	  	 	18	  
	 9.6
	 	Governing Law; Submission to Jurisdiction; Waiver of Trial	  	 	18	  
	 9.7
	 	Survival of Covenants	  	 	18	  
	 9.8
	 	Waivers of Default	  	 	18	  
	 9.9
	 	Force Majeure	  	 	18	  
	 9.10
	 	Notices	  	 	18	  
	 9.11
	 	Termination	  	 	19	  
	 9.12
	 	Changes in Law	  	 	20	  
	 9.13
	 	Severability	  	 	20	  
	 9.14
	 	Entire Agreement	  	 	20	  
	 9.15
	 	Assignment; No Third-Party Beneficiaries	  	 	20	  
	 9.16
	 	Public Announcements	  	 	20	  
	 9.17
	 	Specific Performance	  	 	20	  
	 9.18
	 	Amendment	  	 	21	  
	 9.19
	 	Rules of Construction	  	 	21	  
	 9.20
	 	Counterparts	  	 	21	  

  
 ii 

 SCHEDULES 
  

					
	 SCHEDULE 4.5(A)
		Tax Assets		

  

  
 iii 

 TAX MATTERS AGREEMENT 

This TAX MATTERS AGREEMENT (this “Agreement”) dated
as of [—], 2015, is by and between: JDS Uniphase Corporation, a Delaware corporation which is anticipated to be renamed Viavi Solutions, Inc. (“JDSU”), and Lumentum Holdings
Inc., a Delaware corporation, (“Holdings”). Certain terms used in this Agreement are defined in Section 1.1. 

RECITALS 

WHEREAS, as of the date hereof, JDSU and its direct and indirect domestic subsidiaries are members of an
Affiliated Group, of which JDSU is the common parent; and 
 WHEREAS, the Board of Directors of JDSU
has determined that it is in the best interests of JDSU and its shareholders to create a new publicly traded company to operate the Holdings Business; and 

WHEREAS, pursuant to the CONTRIBUTION AGREEMENT, JDSU
has previously transferred certain assets and liabilities to Lumentum Inc. (“Lumentum”) (the “Contribution”); and 

WHEREAS, pursuant to the SEPARATION, CONTRIBUTION AND
DISTRIBUTION AGREEMENT, among other things, JDSU will contribute all of the issued and outstanding common stock of Lumentum (“Lumentum Common Stock”), par value $[—], to Holdings (the “Separation”); and 

WHEREAS, pursuant to the SEPARATION, CONTRIBUTION AND
DISTRIBUTION AGREEMENT, JDSU will distribute all of the issued and outstanding common stock of Holdings (“Holdings Common Stock”) to the holders of issued and outstanding
shares of the common stock of JDSU (“JDSU Common Stock”) as of the Record Date by means of a pro rata distribution of [—] of Holdings Common Stock for every [—] of JDSU Common Stock held thereby (the “Distribution”); and 

WHEREAS, for U.S. federal income tax purposes, the Contribution contemplated by the
SEPARATION, CONTRIBUTION AND DISTRIBUTION AGREEMENT is intended to constitute a taxable disposition of the Lumentum Assets that results in a tax basis
step-up; and 
 WHEREAS, for U.S. federal income tax purposes, the Separation and Distribution
contemplated by the SEPARATION, CONTRIBUTION AND DISTRIBUTION AGREEMENT, taken together, are intended to qualify as a tax-free transaction pursuant to
sections 355(a) and 368(a)(1)(D) of the Code, and this Agreement is hereby adopted as a plan of reorganization within the meaning of section 368 of the Code and sections 1.368-2(g) and 1.368-3(a) of the United States Income Tax Regulations (the
“Regulations”); and 
 WHEREAS, in contemplation of the Distribution, pursuant
to which the Holdings Group will cease to be members of the Affiliated Group of which JDSU is the common parent, the parties have determined to enter into this Agreement, setting forth their agreement with respect to certain tax matters. 

AGREEMENT 

NOW, THEREFORE, in consideration of the mutual agreements, provisions and covenants
contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound hereby, agree as follows: 

  
 1 

 Article I 

DEFINITIONS 

1.1 Certain Definitions. For purposes of this Agreement, the following terms shall have the meanings specified in this
section: 
 (1) “Active Trade or Business” means the active conduct (as defined in
Section 355(b)(2) of the Code and the regulations thereunder) by Holdings and its “separate affiliated group” (as defined in Section 355(b)(3)(B) of the Code) of the Holdings Business as conducted immediately prior to the
Distribution or by JDSU and its “separate affiliated group” (as defined in Section 355(b)(3)(B) of the Code) of the JDSU Business as conducted immediately prior to the Distribution. 

(2) “Affiliated Group” means an affiliated group of corporations within the meaning of section
1504(a)(1) of the Code that files a consolidated return for United States federal Income Tax purposes. 
 (3)
“After Tax Amount” means any additional amount necessary to reflect the Tax consequences of the receipt or accrual of any payment required to be made under this Agreement (including payment of an additional amount or
amounts hereunder and the effect of the deductions available for interest paid or accrued and for Taxes such as state and local Income Taxes), determined by using the highest applicable statutory corporate Income Tax rate (or rates, in the case of
an item that affects more than one Tax) for the relevant taxable period (or portion thereof). 
 (4)
“Agreement” shall have the meaning set forth in the preamble hereto. 
 (5)
“Audit” means any audit, assessment of Taxes, other examination by any Taxing Authority, proceeding, or appeal of such a proceeding relating to Taxes, whether administrative or judicial, including proceedings relating to
competent authority determinations. 
 (6) “Code” means the Internal
Revenue Code of 1986, as amended. 
 (7) “Combined Return” means any Tax Return, other than with
respect to United States federal Income Taxes, filed on a consolidated, combined (including nexus combination, worldwide combination, domestic combination, line of business combination or any other form of combination) or unitary basis wherein
Holdings or one or more Holdings Affiliates join in the filing of such Tax Return (for any taxable period or portion thereof) with JDSU or one or more JDSU Affiliates. 

(8) “Consolidated Return” means any Tax Return with respect to United States federal Income Taxes filed
on a consolidated basis wherein Holdings or one or more Holdings Affiliates join in the filing of such Tax Return (for any taxable period or portion thereof) with JDSU or one or more JDSU Affiliates. 

(9) “Contribution” shall have the meaning set forth in the recitals hereto. 

(10) “CONTRIBUTION AGREEMENT” MEANS
THE CONTRIBUTION AGREEMENT dated as of [—], 2015, by and between JDSU and Lumentum. 

(11) “Distribution” shall have the meaning set forth in the recitals hereto. 

(12) “Distribution Date” means the date on which the Distribution is effected. 

  
 2 

 (13) “Distribution Effective Time” means the time at which
the Distribution occurs on the Distribution Date, which shall be deemed to be 12:01 a.m., Eastern Daylight Time. 
 (14)
“Estimated Tax Installment Date” means, with respect to United States federal Income Taxes, the estimated Tax installment due dates prescribed in section 6655(c) of the Code and, in the case of any other Tax, means any
other date on which an installment payment of an estimated amount of such Tax is required to be made. 
 (15)
“Filing Party” shall have the meaning set forth in Section 8.1. 
 (16) “Final
Determination” means the final resolution of liability for any Tax for any taxable period, by or as a result of (i) a final and unappealable decision, judgment, decree or other order by any court of competent jurisdiction;
(ii) a final settlement with the IRS, a closing agreement or accepted offer in compromise under section 7121 or section 7122 of the Code, or a comparable agreement under the laws of other jurisdictions, which resolves the entire Tax liability
for any taxable period; (iii) any allowance of a refund or credit in respect of an overpayment of Tax, but only after the expiration of all periods during which such refund may be recovered by the jurisdiction imposing the Tax; or (iv) any
other final disposition, including by reason of the expiration of the applicable statute of limitations. 
 (17)
“Force Majeure” means, with respect to a party, an event beyond the control of such party (or any Person acting on its behalf), which by its nature could not reasonably have been foreseen by such party (or such Person),
or, if it could have reasonably been foreseen, was unavoidable, and includes acts of God, storms, floods, riots, fires, sabotage, civil commotion or civil unrest, interference by civil or military authorities, acts of war (declared or undeclared) or
armed hostilities or other national or international calamity or one (1) or more acts of terrorism or failure of energy sources or distribution facilities. 

(18) “Holdings” shall have the definition set forth in the preamble hereto. 

(19) “Holdings Affiliate” means any corporation or other entity directly or indirectly
“controlled” by Holdings at the time in question, where “control” means the ownership of fifty percent (50%) of the ownership interests of such corporation or other entity (by vote or value) or the possession, directly or
indirectly, of the power to direct or cause the direction of the management or policies of such corporation or other entity. 

(20) “Holdings Business” means the business and operations conducted by Holdings and the Holdings
Affiliates, including the Lumentum Business, as such business and operations will continue after the Distribution Date. 
 (21)
“Holdings Business Records” shall have the meaning set forth in Section 9.2(b). 
 (22)
“Holdings Capital Stock” means all classes or series of capital stock of Holdings, including (i) common stock, (ii) all options, warrants and other rights to acquire such capital stock, and
(iii) all instruments properly treated as stock in Holdings for U.S. federal income tax purposes. 
 (23)
“Holdings Group Assets” shall mean the assets of the Holdings Group after the Distribution Date, as determined under the SEPARATION, CONTRIBUTION AND DISTRIBUTION
AGREEMENT by and among the parties. 
 (24) “Holdings Group” means
the Affiliated Group, or similar group of entities as defined under corresponding provisions of the laws of other jurisdictions, of which Holdings will be the common parent corporation immediately after the Distribution and including any corporation
or other entity which may become a member of such group from time to time. 

  
 3 

 (25) “Holdings Separate Tax Amount” shall
mean with respect to any Tax Return, the amount of Taxes attributable to a Post-Distribution Period that Holdings and each Holdings Affiliate would have incurred if they had filed a consolidated return, combined return or a separate return, as the
case may be, separate from the members of the JDSU Group, for the relevant Tax period, and such amount shall be computed by JDSU in a manner consistent with (i) general Tax accounting principles, (ii) the Code and the Treasury regulations
promulgated thereunder, (iii) applicable provisions of the laws of any other jurisdictions, and (iii) past practice. 

(26) “Income Tax” means any federal, state, local or foreign Tax determined (in whole or in part) by
reference to net income, net worth, gross receipts or capital, or any such Taxes imposed in lieu of such a Tax. For the avoidance of doubt, the term “Income Tax” includes any franchise Tax, net worth, gross receipts, capital or any such
Taxes imposed in lieu of such a Tax. 
 (27) “Income Tax Return” means any Tax Return relating to any
Income Tax. 
 (28) “IRS” means the United States Internal Revenue Service or any successor thereto,
including its agents, representatives, and attorneys. 
 (29) “JDSU” shall have the meaning set forth
in the preamble hereto. 
 (30) “JDSU Affiliate” means any corporation or other entity directly or
indirectly “controlled” by JDSU where “control” means the ownership of fifty percent (50%) of the ownership interests of such corporation or other entity (by vote or value) or the possession, directly or indirectly, of the
power to direct or cause the direction of the management or policies of such corporation or other entity, but at all times excluding Holdings and all Holdings Affiliates. 

(31) “JDSU Business” means all of the businesses and operations conducted by JDSU and the JDSU
Affiliates, excluding the Holdings Business at any time, whether prior to, or after the Distribution Date. 
 (32)
“JDSU Group” means the Affiliated Group, or similar group of entities as defined under corresponding provisions of the laws of other jurisdictions, of which JDSU is the common parent corporation, and any corporation or
other entity which may be, may have been or may become a member of such group from time to time, but excluding any member of the Holdings Group. 

(33) “JDSU Group Assets” shall mean the assets of JDSU after the Distribution Date, as determined under
the SEPARATION, CONTRIBUTION AND DISTRIBUTION AGREEMENT by and among the parties. 

(34) “Lumentum” shall have the meaning set forth in the recitals hereto. 

(35) “Lumentum Assets” means the assets transferred to Lumentum pursuant to the Contribution
Agreement. 
 (36) “Lumentum Business” means the communications and commercial optical products
business of JDSU, including (a) the businesses and operations conducted prior to the Distribution Effective Time by Lumentum, but excluding those businesses set forth on SCHEDULE 1.1(28) of the
CONTRIBUTION AGREEMENT, and (b) any other businesses or operations conducted primarily through the use of Lumentum Assets. 

  
 4 

 (37) “Non-Income Tax Return” means any Tax Return relating
to any Tax other than an Income Tax. 
 (38) “Officer’s Certificate” means a letter executed by
an officer of JDSU or Holdings and provided to Tax Adviser as a condition for the completion of a Tax Opinion. 
 (39)
“Ordinary Course Taxes” means Taxes other than (i) Separation Taxes, (ii) Transfer Taxes and (iii) Taxes resulting from, or arising in connection with, the Contribution. 

(40) “Owed Party” shall have the meaning set forth in Section 7.5. 

(41) “Owing Party” shall have the meaning set forth in Section 7.5. 

(42) “Payment Period” shall have the meaning set forth in Section 7.5(e). 

(43) “Post-Distribution Period” means any taxable period (or portion thereof) beginning after the
Distribution Date. 
 (44) “Pre-Distribution Period” means any taxable period (or portion thereof)
ending on or before the Distribution Date. 
 (45) “Separation” shall have the meaning set forth in
the recitals hereto. 
 (46) “SEPARATION, CONTRIBUTION AND
DISTRIBUTION AGREEMENT” means the SEPARATION, CONTRIBUTION AND DISTRIBUTION AGREEMENT dated as
of [—], 2015, by and between JDSU, Lumentum and Holdings. 
 (47)
“Separation Taxes” means any Taxes imposed on, or increase in Taxes incurred by, JDSU, Holdings or any of their respective Affiliates, and any Taxes imposed on any third party for which JDSU, Holdings or any of their
respective Affiliates is or becomes liable for any reason, resulting from, or arising in connection with, the failure of the Separation and Distribution to qualify as a transaction in which no income, gain or loss is recognized pursuant to sections
355 and 368(a)(1)(D) of the Code (including any Tax resulting from the application of section 355(d) or section 355(e) of the Code to the Separation and Distribution but only to the extent such Tax is not reduced by a Tax Asset) or corresponding
provisions of the laws of any other jurisdictions. 
 (48) “Sole Responsibility Item” means any Tax
Item for which the non-Filing Party has the entire economic liability under this Agreement. 
 (49) “Straddle
Period” shall mean any taxable period that begins on or before and ends after the Distribution Date. 
 (50)
“Supplemental Tax Opinion” shall have the meaning set forth in Section 4.2(c). 
 (51)
“Tax Adviser” means a nationally recognized accounting firm (i) selected by JDSU to provide a Tax Opinion and (ii) selected by the parties, by mutual consent, to provide a Supplemental Tax Opinion. 

  
 5 

 (52) “Tax Asset” means any Tax Item that has accrued for
Tax purposes, but has not been realized during the taxable period in which it has accrued, and that could reduce a Tax in another taxable period, including a net operating loss, net capital loss, research and development tax credit, investment tax
credit, foreign tax credit, charitable deduction or credit related to alternative minimum tax or any other Tax credit. 
 (53)
“Tax Benefit” means a reduction in the Tax liability (or increase in refund or credit or any item of deduction or expense) of a taxpayer (or of the Affiliated Group, or similar group of entities as defined under
corresponding provisions of the laws of any other jurisdiction, of which it is a member) for any taxable period. Except as otherwise provided in this Agreement, a Tax Benefit shall be deemed to have been realized or received from a Tax Item in a
taxable period only if and to the extent that the Tax liability of the taxpayer (or of the Affiliated Group, or similar group of entities as defined under corresponding provisions of the laws of any other jurisdiction, of which it is a member) for
such period, after taking into account the effect of the Tax Item on the Tax liability of such taxpayer (or of the Affiliated Group, or similar group of entities as defined under corresponding provisions of the laws of any other jurisdiction, of
which it is a member) in the current period and all prior periods, is less than it would have been had such Tax liability been determined without regard to such Tax Item. 

(54) “Tax Detriment” means an increase in the Tax liability (or reduction in refund or credit or any
item of deduction or expense) of a taxpayer (or of the Affiliated Group, or similar group of entities as defined under corresponding provisions of the laws of any other jurisdiction, of which it is a member) for any taxable period. Except as
otherwise provided in this Agreement, a Tax Detriment shall be deemed to have been realized or incurred from a Tax Item in a taxable period only if and to the extent that the Tax liability of the taxpayer (or of the Affiliated Group, or similar
group of entities as defined under corresponding provisions of the laws of any other jurisdiction, of which it is a member) for such period, after taking into account the effect of the Tax Item on the Tax liability of such taxpayer (or of the
Affiliated Group, or similar group of entities as defined under corresponding provisions of the laws of any other jurisdiction, of which it is a member) in the current period and all prior periods, is more than it would have been had such Tax
liability been determined without regard to such Tax Item. 
 (55) “Tax Item” means any item of
income, gain, loss, deduction, expense or credit, or other attribute that may have the effect of increasing or decreasing any Tax. 

(56) “Tax Opinion” means an opinion issued by Tax Adviser as one of the conditions to completing the
Distribution addressing certain United States federal Income Tax consequences of the Distribution under sections 355 and 368(a)(1)(D) of the Code 

(57) “Tax Return” means any return, report, certificate, form or similar statement or document
(including any related or supporting information or schedule attached thereto and any information return, amended tax return, claim for refund or declaration of estimated Tax) required to be supplied to, or filed with, a Taxing Authority in
connection with the determination, assessment or collection of any Tax or the administration of any laws, regulations or administrative requirements relating to any Tax. 

(58) “Taxes” means all federal, state, local or foreign taxes, charges, fees, duties, levies, imposts,
rates or other assessments, including income, gross receipts, excise, property, excise, severance, stamp, occupation, premium, windfall profits, environmental (including taxes under Code §59A), customs duties, profits, sales, use, license,
capital stock, transfer, registration, franchise, payroll, unemployment, disability, withholding, social security, value added, alternative or add-on minimum, estimated, or other tax of any kind whatsoever, (including any interest, penalties or
additions attributable thereto and including any obligations to indemnify or otherwise assume or succeed to the Tax liability of any other Person) and a “Tax” shall mean any one of such Taxes. 

  
 6 

 (59) “Taxing Authority” means any governmental authority or
any subdivision, agency, commission or authority thereof or any quasi-governmental or private body having jurisdiction over the assessment, determination, collection or imposition of any Tax (including the IRS). 

(60) “Transfer Taxes” means all transfer, sales, use, excise, stock, stamp, stamp duty, stamp duty
reserve, stamp duty land, documentary, filing, recording, registration, value-added and other similar Taxes (excluding, for the avoidance of doubt, any income, gains, profit or similar Taxes, however assessed). 

1.2 Other Terms. For purposes of this Agreement, the following terms have the meanings set forth in the sections
indicated: 
  

			
	 Term
		 Section

	 Dispute
		Section 9.3
	 Holdings Common Stock
		Recitals
	 Initial Notice
		Section 9.3(b)
	 JDSU Common Stock
		Recitals
	 Law
		Section 1.1(32) of the CONTRIBUTION AGREEMENT
	 Lumentum Common Stock
		Recitals
	 Person
		Section 1.1(33) of the CONTRIBUTION AGREEMENT
	 PLR
		Section 4.2(c)
	 Record Date
		Section 1.1(28) of the SEPARATION, CONTRIBUTION AND DISTRIBUTION AGREEMENT
	 Regulations
		Recitals
	 Response
		Section 9.3(b)

 Article II 

PREPARATION AND FILING OF TAX RETURNS 

2.1 DSU’s Responsibility. Subject to the other applicable provisions of this Agreement, JDSU shall have sole and
exclusive responsibility for the preparation and filing of: 
 (a) all Consolidated Returns and all Combined Returns for any
taxable period; 
 (b) all Income Tax Returns (other than Consolidated Returns and Combined Returns) with respect to JDSU
and/or any JDSU Affiliate for any taxable period; 

  
 7 

 (c) all Non-Income Tax Returns with respect to JDSU, any JDSU Affiliate, or the
JDSU Business or any part thereof for any taxable period; and 
 (d) all Non-Income Tax Returns with respect to Holdings, any
Holdings Affiliate, or the Holdings Business or any part thereof, that are required to be filed for any taxable period (taking into account any extension of time which has been requested or received) on or prior to the Distribution Date. 

2.2 Holdings’ Responsibility. Holdings shall have sole and exclusive responsibility for the preparation and
filing of: 
 (a) all Income Tax Returns (other than Consolidated Returns and Combined Returns) with respect to Holdings
and/or any Holdings Affiliate for any taxable period that are required to be filed after the Distribution Date; and 
 (b) all
Non-Income Tax Returns with respect to Holdings, any Holdings Affiliate, or the Holdings Business or any part thereof, that are required to be filed for any taxable period (taking into account any extension of time which has been requested or
received) after the Distribution Date. 
 2.3 Agent. Subject to the other applicable provisions of this
Agreement, Holdings hereby irrevocably designates, and agrees to cause each Holdings Affiliate to so designate, JDSU as its sole and exclusive agent and attorney-in-fact to take such action (including execution of documents) as JDSU, in its sole
discretion, may deem appropriate in any and all matters (including Audits) relating to any Tax Return described in Section 2.1 subject, however, to the joint control provisions and control by a non-Filing Party provisions in Section
8. 
 2.4 Manner of Tax Return Preparation. 

(a) Unless otherwise required by a Taxing Authority, the parties hereby agree to prepare and file all Tax Returns, and to take
all other actions, in a manner consistent with this Agreement. All Tax Returns shall be filed on a timely basis (taking into account applicable extensions) by the party responsible for filing such returns under this Agreement. 

(b) Subject to the other applicable provisions of this Agreement, JDSU and Holdings shall each have the exclusive right, in its
sole discretion, with respect to any Tax Return for which it is responsible under Sections 2.1 and 2.2, to determine (1) the manner in which such Tax Return shall be prepared and filed, including the elections, method of
accounting, positions, conventions and principles of taxation to be used and the manner in which any Tax Item shall be reported, (2) whether any extensions shall be requested, (3) the elections that will be made on such Tax Return,
(4) whether any amended Tax Returns shall be filed, (5) whether any claims for refund shall be made, (6) whether any refunds shall be paid by way of refund or credited against any liability for the related Tax, and (7) whether to
retain outside firms to prepare and/or review such Tax Returns. 
 Article III 

LIABILITY FOR ORDINARY COURSE TAXES 

3.1 JDSU’s Liability for Ordinary Course Taxes and Contribution. JDSU shall be liable for Taxes resulting
from, or arising in connection with, the Contribution and for the following Ordinary Course Taxes, and shall be entitled to receive and retain all refunds of: 

  
 8 

 (a) all Ordinary Course Taxes attributable to the JDSU Group, the JDSU Group Assets
or the JDSU Business, in each case for any and all periods, 
 (b) except with respect to foreign Holdings Affiliates, all
Ordinary Course Taxes attributable to the Holdings Group, the Holdings Group Assets or the Holdings Business, in each case for any and all Pre-Distribution Periods, 

(c) all Ordinary Course Taxes for which the Holdings Group may be liable by virtue of any agreement or arrangement with respect
to Taxes (other than pursuant to this Agreement or any other agreements entered into in connection with the Distribution) entered into on or prior to the Distribution Date. 

3.2 Holdings’ Liability for Ordinary Course Taxes. Holdings and each Holdings Affiliate shall be liable for
(i) all Ordinary Course Taxes attributable to any and all members of the Holdings Group or the Holdings Group Assets or the Holdings Business, in each case for any and all Post-Distribution Periods and (ii) all Ordinary Course Taxes
attributable to foreign Holdings Affiliates for any and all periods. 
 3.3 Straddle Periods. For purposes of
Sections 3.1 and 3.2, in the case of any Straddle Period, (i) property taxes and exemptions, allowances or deductions that are calculated on an annualized basis shall be apportioned between the Pre-Distribution Period and the
Post-Distribution Period on a daily pro-rata basis and (ii) all other Ordinary Course Taxes shall be apportioned between the Pre-Distribution Period and the Post-Distribution Period on a closing of the books basis as of the close of business on
the Distribution Date. 
 3.4 Refunds. The amount of any refunds, credits or offsets of Ordinary Course Taxes
relating to (i) the Holdings Group (other than foreign Holdings Affiliates), the Holdings Group Assets or the Holdings Business for a Pre-Distribution Period shall be for the account of JDSU, (ii) the Holdings Group, the Holdings Group
Assets or the Holdings Business for a Post-Distribution Period shall be for the account of Holdings, and (iii) the JDSU Group, the JDSU Group Assets or the JDSU Business shall for the account of JDSU. 

3.5 Payment of Tax Liability. If one party is liable or responsible for Taxes, under Sections 3.1 through
3.3, with respect to Tax Returns for which another party is responsible for preparing and/or filing, or with respect to Taxes that are paid by another party, then the liable or responsible party shall pay the Taxes (or a reimbursement of such
Taxes) to the other party pursuant to Section 7.5. 
 3.6 Computation. With respect to any Tax Return
filed by JDSU for which Holdings is liable for Taxes under this Article III, JDSU shall provide Holdings with a written calculation in reasonable detail (including copies of work sheets and other materials used in preparation thereof) setting
forth the amount of any Holdings Separate Tax Amount or estimated Holdings Separate Tax Amount (for purposes of Section 7.1). Holdings shall have the right to review and comment on such calculation. Any dispute with respect to such
calculation shall be resolved pursuant to Section 9.3; provided, however, that, notwithstanding any dispute with respect to any such calculation, in no event shall any payment attributable to the amount of any Holdings
Separate Tax Amount or estimated Holdings Separate Tax Amount be paid later than the date provided in Section 7. 

  
 9 

 Article IV 

SEPARATION TAXES, TRANSFER TAXES, TAX ITEMS AND TAX ASSETS 

4.1 Separation Taxes. 

(a) JDSU’s Liability for Separation Taxes. JDSU shall be liable for any Separation Taxes other than such
Taxes for which Holdings is liable under Section 4.1(b). 
 (b) Holdings’ Liability for Separation
Taxes. Holdings shall be liable for any Separation Taxes attributable to, caused by, or result from, one or more of the following: 

(i) any action or omission by Holdings (or any Holdings Affiliate) after the Distribution at any time, that is inconsistent
with any material, information, covenant or representation related to Holdings, any Holdings Affiliate, or the Holdings Business in an Officer’s Certificate, Tax Opinion or Supplemental Tax Opinion; 

(ii) any action or omission by Holdings (or any Holdings Affiliate), after the Distribution Date (including any act or omission
that is in furtherance of, connected to, or part of a plan or series of related transactions (within the meaning of section 355(e) of the Code) occurring on or prior to the Distribution Date) including a cessation, transfer to affiliates or
disposition of the Active Trade or Business, stock buyback or payment of an extraordinary dividend; 
 (iii) any acquisition
of any stock or assets of Holdings (or any Holdings Affiliate) by one or more other persons (other than JDSU or any JDSU Affiliate) following the Distribution; 

(iv) any issuance of stock by Holdings (or any Holdings Affiliate) after the Distribution, including any issuance pursuant to
the exercise of employee stock options or other employment related arrangements or the exercise of warrants, or change in ownership of stock in Holdings (or any Holdings Affiliate) after the Distribution; 

(v) any action or omission by Holdings (or any Holdings Affiliate) in breach of the covenants set forth herein, or in the
Separation, Contribution and Distribution Agreement. 
 (c) Representations. Each of JDSU and Holdings represents that,
as of the date of this Agreement, neither it nor its Affiliates know of any fact that may cause the Separation and Distribution to fail to qualify under section 355 or section 368(a)(1)(D) of the Code. Each of JDSU and Holdings further represents
that (A) it has examined the Tax Opinion and Officer’s Certificates prior to the date hereof and (B) subject to any qualifications therein, all facts contained in such Tax Opinion or Officer’s Certificates that concern or relate
to such JDSU, Holdings or any member of its Group is and, to the extent such facts relate to future events or circumstances, will be, true, correct and complete. 

4.2 Continuing Covenants. 

(a) In General. Each of JDSU (for itself and each JDSU Affiliate) and Holdings (for itself and each Holdings
Affiliate) agrees (1) not to take any action reasonably expected to result in an increased Tax liability to the other, a reduction in a Tax Asset of the other or an increased liability to the other under this Agreement, and (2) to take any
action reasonably requested by the other that would reasonably be expected to result in a Tax Benefit or avoid a Tax Detriment to the other, provided, in either such case, that the taking or refraining to take such action does not result in any
additional cost not 

  
 10 

 
fully compensated for by the other party or any other adverse effect to such party. The parties hereby acknowledge that the preceding sentence is not intended to limit, and therefore shall not
apply to, the rights of the parties with respect to matters otherwise covered by this Agreement. 
 (b) Holdings
Restrictions. Holdings agrees that it will not knowingly take or fail to take, or permit any Holdings Affiliate to knowingly take or fail to take, any action where such action or failure to act would be inconsistent with any material,
information, covenant or representation that relates to facts or matters related to Holdings (or any Holdings Affiliate) or within the control of Holdings and is contained in an Officer’s Certificate, Tax Opinion or Supplemental Tax Opinion
(except where such material, information, covenant or representation was not previously disclosed to Holdings) other than as permitted in this Section 4.2. For this purpose an action is considered inconsistent with a representation if
the representation states that there is no plan or intention to take such action. Holdings agrees that it will not take (and it will cause the Holdings Affiliates to refrain from taking) any position on a Tax Return that is inconsistent with the
treatment of the Separation and Distribution as transactions in which no income, gain, or loss is recognized pursuant to sections 355 and 368(a)(1)(D) of the Code. 

(c) Certain Holdings Actions Following the Distribution. Holdings agrees that, during the two (2) year period
following the Distribution, without first obtaining, at Holdings’ own expense, a private letter ruling (a “PLR”) from the IRS or supplemental opinion from Tax Adviser that such action will not result in Separation Taxes
(a “Supplemental Tax Opinion”), unless JDSU and Holdings agree otherwise in writing, Holdings shall not (1) sell all or substantially all of the assets of Holdings or any Holdings Affiliate , (2) merge Holdings, or
any Holdings Affiliate with another entity, without regard to which party is the surviving entity (other than a merger with another entity within the Holdings Group), (3) transfer any assets of Holdings or Holdings Affiliate in a transaction
described in section 351of the Code (other than a transfer to a corporation which files a consolidated return with Holdings and which is wholly-owned, directly or indirectly, by Holdings) or subparagraph (C) or (D) of section 368(a)(1) of
the Code, (4) issue stock of Holdings or any Holdings Affiliate (or any instrument that is convertible or exchangeable into any such stock) in an acquisition or public or private offering (excluding any issuance pursuant to the exercise of
employee stock options or other employment related arrangements having customary terms and conditions and that satisfy the requirements of Treasury Regulations section 1.355-7(d)(8), or any successor provision thereto), or (5) facilitate or
otherwise participate in any acquisition of stock in Holdings that would result in any shareholder owning five percent (5%) or more of the outstanding stock of Holdings. Holdings (or any Holdings Affiliate) shall only undertake any of such
actions after JDSU’s receipt of such Supplemental Tax Opinion and pursuant to the terms and conditions of any such Supplemental Tax Opinion or as otherwise consented to in writing in advance by JDSU; provided,
however, that if Holdings contemplates entering into a transaction described in this section and Holdings acknowledges in writing that it would have sole liability for any Separation Taxes under Section 4.1(b) that might arise
from such transaction and can demonstrate to the reasonable satisfaction of JDSU that it can satisfy its liability for any such Separation Taxes, JDSU shall consent to Holdings’ entering into such transaction without further restriction; and
provided, further, that in the event that JDSU completes a transaction that results in a tax being imposed on JDSU under Section 355(e) of the Code, after such completion, Holdings shall no longer be subject to the restrictions
under clause (4) and clause (5) of the previous sentence. The Parties hereby agree that they will act in good faith to take all reasonable steps necessary to amend this Section 4.2(c), from time to time, by mutual agreement, to
(i) add certain actions to the list contained herein, or (ii) remove certain actions from the list contained herein, in either case, in order to reflect any relevant change in law, regulation or administrative interpretation occurring
after the date of this Agreement. 
 (d) Notice of Specified Transactions. Not later than three (3) days
after the public announcement regarding any of the transactions described in Section 4.2(c) (including a public announcement regarding Holdings’ intent to enter into any such transaction) Holdings shall provide written notice of
such transaction to JDSU. 

  
 11 

 4.3 Transfer Taxes. JDSU and Holdings each shall be responsible for
any Transfer Taxes incurred by the JDSU Group and the Holdings Group, respectively, as a result of the Contribution. If, under applicable Law, both the JDSU Group and the Holdings Group are liable for Transfer Taxes resulting from the Contribution,
then JDSU and Holdings shall be equally responsible for such Transfer Taxes. 
 4.4 Allocation of Tax Items. All
Tax computations for (1) any Pre-Distribution Periods ending on the Distribution Date and (2) the immediately following taxable period of Holdings or any Holdings Affiliate, shall be made pursuant to the principles of section 1.1502-76(b)
of the Treasury Regulations or of a corresponding provision under the laws of other jurisdictions, as reasonably determined by JDSU, taking into account all reasonable suggestions made by Holdings with respect thereto. Any Tax Items relating to the
Separation and Distribution shall be treated, to the extent permitted, as extraordinary items described in section 1.1502-76(b)(2)(ii)(C) of the Treasury Regulations and shall (to the extent occurring on or prior to the Distribution Date) be
allocated to Pre- Distribution Periods, and any Taxes related to such items shall be treated under section 1.1502-76(b)(2)(iv) of the Treasury Regulations as relating to such extraordinary item and shall (to the extent occurring on or prior to the
Distribution Date) be allocated to Pre-Distribution Periods. 
 4.5 Allocation of Tax Assets. 

(a) In General. In connection with the Distribution, JDSU and Holdings have set forth on
SCHEDULE 4.5(A) the Tax Assets allocated to JDSU and Holdings, and each of JDSU and Holdings agrees that each shall prepare all Tax Returns in a manner consistent with such allocation, unless otherwise required
by law. The parties hereby agree that to the extent that Tax Assets are not shown in SCHEDULE 4.5(A), such Tax Assets were incurred by JDSU and shall remain with JDSU. 

(b) Earnings and Profits. JDSU will advise Holdings in writing of the decrease in JDSU earnings and profits
attributable to the Distribution under section 312(h) of the Code on or before the first anniversary of the Distribution Date; provided, however, that JDSU shall provide Holdings with estimates of such amounts (determined in accordance
with past practice) prior to such anniversary as reasonably requested by Holdings. 
 Article V 

EMPLOYEE WAGES 
 At
JDSU’s request, the Holdings Group shall assume the Form W-2 and Form W-3 reporting obligations (including the filing of all forms necessary to comply with magnetic media reporting requirements) of JDSU with respect to any employee of the
Holdings Business that Holdings or any Holdings Affiliate employs during the calendar year which includes the Distribution Date consistent with the procedures set forth in section 5 of Rev. Proc. 2004-53, 2004-34 I.R.B. 320. 

Article VI 

INDEMNIFICATION 

6.1 In General. JDSU and each member of the JDSU Group shall jointly and severally indemnify Holdings, each
Holdings Affiliate, and their respective directors, officers and employees, and 

  
 12 

 
hold them harmless from and against any and all Taxes for which JDSU or any JDSU Affiliate is liable under this Agreement and any loss, cost, damage or expense, including reasonable
attorneys’ fees and costs, that is attributable to, or results from, the failure of JDSU, any JDSU Affiliate or any director, officer or employee to make any payment required to be made under this Agreement. Holdings and each member of the
Holdings Group shall jointly and severally indemnify JDSU, each JDSU Affiliate, and their respective directors, officers and employees, and hold them harmless from and against any and all Taxes for which Holdings or any Holdings Affiliate is liable
under this Agreement and any loss, cost, damage or expense, including reasonable attorneys’ fees and costs, that is attributable to, or results from, the failure of Holdings, any Holdings Affiliate or any director, officer or employee to make
any payment required to be made under this Agreement. 
 6.2 Inaccurate or Incomplete Information. JDSU and each
member of the JDSU Group shall jointly and severally indemnify Holdings, each Holdings Affiliate, and their respective directors, officers and employees, and hold them harmless from and against any cost, fine, penalty, or other expense of any kind
attributable to the failure of JDSU or any JDSU Affiliate in supplying Holdings or any Holdings Affiliate with inaccurate or incomplete information, in connection with the preparation of any Tax Return. Holdings and each member of the Holdings Group
shall jointly and severally indemnify JDSU, each JDSU Affiliate, and their respective directors, officers and employees, and hold them harmless from and against any cost, fine, penalty, or other expenses of any kind attributable to the failure of
Holdings or any Holdings Affiliate in supplying JDSU or any JDSU Affiliate with inaccurate or incomplete information, in connection with the preparation of any Tax Return. 

6.3 No Indemnification for Tax Items. Nothing in this Agreement shall be construed as a guarantee of the existence
or amount of any loss, credit, carryforward, basis or other Tax Item, whether past, present or future, of JDSU, any JDSU Affiliate, Holdings or any Holdings Affiliate. In addition, for the avoidance of doubt, for purposes of determining any amount
owed between the parties hereto, all such determinations shall be made without regard to any financial accounting tax asset or liability or other financial accounting items. 

Article VII 

PAYMENTS 

7.1 Estimated Tax Payments. Not later than ten (10) business days after each Estimated Tax Installment Date
with respect to a taxable period for which a Consolidated Return or a Combined Return that includes a Holdings Separate Tax Amount will be filed, Holdings shall pay to JDSU on behalf of the Holdings Group an amount equal to the amount of any
estimated Holdings Separate Tax Amount. 
 7.2 True-Up Payments. Not later than ten (10) business days
after filing a Tax Return, Holdings shall pay to JDSU, or JDSU shall pay to Holdings, as appropriate, an amount equal to the difference, if any, between the Holdings Separate Tax Amount and the aggregate amount paid by Holdings with respect to such
period under Section 7.1. 
 7.3 Redetermination Amounts. In the event of a redetermination of any Tax
Item reflected on any Consolidated Return or Combined Return (other than Tax Items relating to Separation Taxes), as a result of a refund of Taxes paid, a Final Determination or any settlement or compromise with any Taxing Authority which in any
such case would affect the Holdings Separate Tax Amount, JDSU shall prepare a revised pro forma Tax Return in accordance with Section 2.4(b) for the relevant taxable period reflecting the redetermination of such Tax Item as a result of
such refund, Final Determination, settlement or compromise. Holdings shall pay to JDSU, or JDSU shall pay to Holdings, as appropriate, an amount equal to the difference, if any, between the Holdings Separate Tax Amount reflected on such revised pro
forma Tax Return and the Holdings Separate Tax Amount for such period as originally computed pursuant to this Agreement. 

  
 13 

 7.4 Payments of Refunds and Credits. If one party receives a refund
or credit of any Tax to which the other party is entitled pursuant to Section 3.4, the party receiving such refund or credit shall pay to the other party the amount of such refund or credit pursuant to Section 7.5. 

7.5 Payments Under This Agreement. In the event that one party (the “Owing Party”) is
required to make a payment to another party (the “Owed Party”) pursuant to this Agreement, then such payments shall be made according to this Section 7.5. 

(a) In General. All payments shall be made to the Owed Party or to the appropriate Taxing Authority as specified
by the Owed Party within the time prescribed for payment in this Agreement, or if no period is prescribed, within ten (10) days after delivery of written notice of payment owing together with a computation of the amounts due. 

(b) Treatment of Payments. Unless otherwise required by any Final Determination, the parties agree that any
payments made by one party to another party pursuant to this Agreement (other than (i) payments for the Holdings Separate Tax Amount for the Post-Distribution Period, (ii) payments of After Tax Amounts pursuant to
Section 7.5(d), and (iii) payments of interest pursuant to Section 7.5(e)) shall be treated for all Tax purposes as nontaxable payments (dividend distributions or capital contributions, as the case may be) made
immediately prior to the Distribution and, accordingly, as not includible in the taxable income of the recipient or as deductible by the payor. 

(c) Prompt Performance. All actions required to be taken (including payments) by any party under this Agreement
shall be performed within the time prescribed for performance in this Agreement, or if no period is prescribed, such actions shall be performed promptly. 

(d) After Tax Amounts. If pursuant to a Final Determination it is determined that the receipt or accrual of any
payment made under this Agreement (other than payments of interest pursuant to Section 7.5(e)) is subject to any Tax, the party making such payment shall be liable for (a) the After Tax Amount with respect to such payment and
(b) interest at the rate described in Section 7.5(e) on the amount of such Tax from the date such Tax accrues through the date of payment of such After Tax Amount. A party making a demand for a payment pursuant to this Agreement and
for a payment of an After Tax Amount with respect to such payment shall separately specify and compute such After Tax Amount. However, a party may choose not to specify an After Tax Amount in a demand for payment pursuant to this Agreement without
thereby being deemed to have waived its right subsequently to demand an After Tax Amount with respect to such payment. 
 (e)
Interest. Payments pursuant to this Agreement that are not made within the period prescribed in this Agreement (the “Payment Period”) shall bear interest for the period from and including the date immediately
following the last date of the Payment Period through and including the date of payment at a per annum rate equal to the applicable rate under Section 6621 of the Code. Such interest will be payable at the same time as the payment to which it
relates and shall be calculated on the basis of a year of three hundred sixty-five (365) days and the actual number of days for which due. 

  
 14 

 Article VIII 

TAX PROCEEDINGS 

8.1 In General. Except as otherwise provided in this Agreement, the party responsible for preparing and filing a Tax
Return pursuant to Article II (the “Filing Party”) shall have the exclusive right, in its sole discretion, to control, contest, and represent the interests of JDSU, any JDSU Affiliate, Holdings, and/or any Holdings
Affiliate in any Audit relating to such Tax Return and to resolve, settle or agree to any deficiency, claim or adjustment proposed, asserted or assessed in connection with or as a result of any such Audit; provided, however, that for purposes of
this Section 8, Holdings shall be treated as the Filing Party for all Tax Returns of foreign Holdings Affiliates. The Filing Party’s rights shall extend to any matter pertaining to the management and control of an Audit, including
execution of waivers, choice of forum, scheduling of conferences and the resolution of any Tax Item. Any costs incurred in handling, settling, or contesting an Audit shall be borne by the Filing Party. 

8.2 Participation of non-Filing Party. Except as provided in Section 8.4, the non-Filing Party shall,
at its own expense, have control over decisions to resolve, settle or otherwise agree to any deficiency, claim or adjustment with respect to any Sole Responsibility Item. 

8.3 Notice. Within ten (10) days after a party receives written notice of a proposed Audit adjustment that
may give rise to an indemnification obligation under this Agreement, such party shall give notice to the other party of such issue (such notice shall contain factual information, to the extent known, describing any asserted tax liability in
reasonable detail), and shall forward to the other party copies of all notices and material communications with any Taxing Authority relating to such issue. Notwithstanding any provision in Section 9.12 to the contrary, if a party to
this Agreement fails to provide the other party notice as required by this Section 8.3, and the failure results in a detriment to the other party then any amount which the other party is otherwise required to pay pursuant to this
Agreement shall be reduced by the amount of such detriment. 
 8.4 Control of Separation Tax Proceedings. JDSU
shall have the exclusive right, in its sole discretion, to control, contest, and represent the interests of JDSU, any JDSU Affiliate, Holdings, and/or any Holdings Affiliate in any Audits relating to Separation Taxes and to resolve, settle or agree
to any deficiency, claim or adjustment proposed, asserted or assessed in connection with or as a result of any such Audit. JDSU’s rights shall extend to any matter pertaining to the management and control of such Audit, including execution of
waivers, choice of forum, scheduling of conferences and the resolution of any Tax Item. Holdings may assume sole control of any Audits relating to Separation Taxes if it acknowledges in writing that it has sole liability for any Separation Taxes
under Section 4.1(b) that might arise in such Audit and can demonstrate to the reasonable satisfaction of JDSU that it can satisfy its liability for any such Separation Taxes. If Holdings is unable to demonstrate to the reasonable
satisfaction of JDSU that it will be able to satisfy its liability for such Separation Taxes, but acknowledges in writing that it has sole liability for any Separation Taxes under Section 4.1(b), Holdings and JDSU shall have joint
control over the Audit. 
 Article IX 

MISCELLANEOUS PROVISIONS 

9.1 Corporate Power; Facsimile Signatures. 

(a) Holdings, on behalf of itself and any Holdings Affiliate, and JDSU, on behalf of itself and any JDSU Affiliate, hereby
represent as follows: 

  
 15 

 (i) each such Person has the requisite corporate power and authority and has taken
all corporate action necessary in order to execute, deliver and perform this Agreement and to consummate the transactions contemplated hereby and thereby; and 

(ii) this Agreement has been duly executed and delivered by it and constitutes a valid and binding agreement of it enforceable
in accordance with the terms thereof. 
 (b) Each party acknowledges that it and each other party may execute this Agreement
by facsimile, stamp or mechanical signature, and that delivery of an executed counterpart of a signature page to this Agreement (whether executed by manual, stamp or mechanical signature) by facsimile or by email in portable document format (.pdf)
shall be effective as delivery of such executed counterpart of this Agreement. Each party expressly adopts and confirms each such facsimile, stamp or mechanical signature (regardless of whether delivered in person, by mail, by courier, by facsimile
or by email in .pdf) made in its respective name as if it were a manual signature delivered in person, agrees that it will not assert that any such signature or delivery is not adequate to bind such party to the same extent as if it were signed
manually and delivered in person and agrees that, at the reasonable request of the other party at any time, it will as promptly as reasonably practicable cause this Agreement to be manually executed (any such execution to be as of the date of the
initial date thereof) and delivered in person, by mail or by courier. 
 9.2 Cooperation and Separation of
Information. 
 (a) Cooperation. Holdings and JDSU shall each cooperate fully (and each shall cause its
respective affiliates to cooperate fully) with all reasonable requests from another party for information and materials not otherwise available to the requesting party in connection with the preparation and filing of Tax Returns, claims for refund,
and Audits concerning issues or other matters covered by this Agreement or in connection with the determination of a liability for Taxes or a right to a refund of Taxes. Such cooperation shall include: 

(i) the retention until the expiration of the applicable statute of limitations, and the provision upon request, of copies of
all Tax Returns, books, records (including information regarding ownership and Tax basis of property), documentation and other information relating to the Tax Returns, including accompanying schedules, related work papers, and documents relating to
rulings or other determinations by Taxing Authorities; 
 (ii) the execution of any document that may be necessary or
reasonably helpful in connection with any Tax Proceeding, or the filing of a Tax Return or refund claim by a member of the JDSU Group or the Holdings Group, including certification, to the best of a party’s knowledge, of the accuracy and
completeness of the information it has supplied; and 
 (iii) the use of the party’s commercially reasonable efforts to
obtain any documentation that may be necessary or reasonably helpful in connection with any of the foregoing. Each party shall make its employees and facilities available on a reasonable and mutually convenient basis in connection with the foregoing
matters. 
 (b) Retention of Records. Any party that is in possession of documentation of JDSU (or any JDSU Affiliate)
or Holdings (or any Holdings Affiliate) relating to the Holdings Business, including books, records, Tax Returns and all supporting schedules and information relating thereto (the “Holdings Business Records”) shall retain
such Holdings Business Records for a period of seven (7) years following the Separation Date. Thereafter, any party wishing to dispose of Holdings Business Records in its possession (after the expiration of the applicable statute of
limitations), shall provide 

  
 16 

 
written notice to the other party describing the documentation proposed to be destroyed or disposed of sixty (60) business days prior to taking such action. The other party may arrange to
take delivery of any or all of the documentation described in the notice at its expense during the succeeding sixty (60) day period. 

9.3 Dispute Resolution. Any dispute, controversy or claim arising out of or relating to this Agreement or the
validity, interpretation, breach or termination thereof (a “Dispute”), shall be resolved in accordance with the procedures set forth in this Section 9.3: 

(a) General Provisions. All communications between the parties or their representatives in connection with the attempted resolution of any
Dispute shall be deemed to have been delivered in furtherance of a Dispute settlement and shall be exempt from discovery and production, and shall not be admissible into evidence for any reason (whether as an admission or otherwise), in any arbitral
or other proceeding for the resolution of any Dispute. 
 WITH RESPECT TO ANY
DISPUTE TO WHICH THIS SECTION 9.3 APPLIES OR OTHERWISE IN RESPECT OF
THIS AGREEMENT, THE PARTIES EXPRESSLY WAIVE AND FOREGO ANY RIGHT TO
EXEMPLARY, SPECIAL, PUNITIVE, INDIRECT, REMOTE, SPECULATIVE OR CONSEQUENTIAL DAMAGES (INCLUDING
IN RESPECT OF LOST PROFITS OR REVENUES), HOWEVER CAUSED AND ON ANY
THEORY OF LIABILITY (INCLUDING NEGLIGENCE), WHETHER OR NOT SUCH PARTY HAS
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES (PROVIDED THAT
LIABILITY FOR ANY SUCH DAMAGES WITH RESPECT TO ANY THIRD PARTY CLAIM
AND ANY STATUTORY PENALTIES UNDER ENVIRONMENTAL LAW SHALL BE CONSIDERED DIRECT
DAMAGES). 
 The specific procedures set forth in this Section 9.3, including the time limits referenced therein, may be modified
by agreement of both of the parties in writing. All applicable statutes of limitations and defenses based upon the passage of time shall be tolled while the procedures specified in this Section 9.3 are pending. The parties will take any
necessary or appropriate action required to effectuate such tolling. Unless otherwise agreed in writing, the parties will continue to provide service and honor all other commitments under this Agreement during the course of resolution of a Dispute
pursuant to the provisions of this Section 9.3 with respect to all matters not subject to such Dispute. 
 (b)
Consideration by Senior Executives. If a Dispute is not resolved in the normal course of business at the operational level, the parties shall attempt in good faith to resolve the Dispute by negotiation among representatives of the
parties at a senior level of management of the parties. Either party may initiate such executive negotiation process by providing a written notice to the other (the “Initial Notice”). Within thirty (30) days after
delivery of the Initial Notice, the receiving party shall submit to the other a written response (the “Response”). The Initial Notice and the Response shall include (i) a statement of the Dispute and of each party’s
position and (ii) the name and title of the executive who will represent that party and of any other Person who will accompany the executive. The parties agree that such executives shall have full and complete authority to resolve any Disputes
submitted pursuant to this section (or paragraph). Such executives will meet in person or by teleconference or video conference within sixty (60) days of the date of the Initial Notice to seek a resolution of the Dispute. In the event that the
executives are unable to agree to a format for such meeting, the meeting shall be convened by teleconference. In the event that the executives are unable to resolve such Dispute within ninety (90) days of the date of the Initial Notice, the
parties may seek any and all other remedies as may be available to them at law or equity. 
 (c) Mediation. The parties
may, by mutual consent, select a mediator to aid the parties in their discussions and negotiations. Any opinion expressed by the mediator shall be strictly advisory and shall not be binding on the parties, nor shall any opinion expressed by the
mediator be 

  
 17 

 
admissible in any arbitration proceeding. Each party shall bear its own fees, costs and expenses and an equal share of the expenses of the mediation. Each party shall designate a business
executive to have full and complete authority to resolve the Dispute and to represent its interests in the mediation, and each party may, in its sole discretion, include any number of other Representatives in the mediation process. 

9.4 Confidentiality. The parties shall comply with the confidentiality provisions in Section 5.4 of
the SEPARATION, CONTRIBUTION AND DISTRIBUTION AGREEMENT. 

9.5 Setoff. All payments to be made by any party under this Agreement may be netted against payments due to such
party under this Agreement, but otherwise shall be made without setoff, counterclaim or withholding, all of which are hereby expressly waived. 

9.6 Governing Law; Submission to Jurisdiction; Waiver of Trial. 

(a) This Agreement shall be governed by and construed and interpreted in accordance with the Laws of the State of Delaware
without giving effect to the principles of conflicts of law thereof. 
 (b) Each party to this Agreement hereby irrevocably
(i) agrees that any Dispute shall be subject to the exclusive jurisdiction of the state and federal courts located in the State of Delaware, (ii) waives any claims of forum non conveniens, and agrees to submit to the jurisdiction of such
courts and (iii) agrees that service of any process, summons, notice or document by U.S. registered mail to its respective address set forth in Section 9.10 shall be effective service of process for any litigation brought against it
in any such court or for the taking of any other acts as may be necessary or appropriate in order to effectuate any judgment of said courts. 

9.7 Survival of Covenants. Except as expressly set forth in this Agreement, the covenants and other agreements
contained in this Agreement, and liability for the breach of any obligations contained herein or therein, shall survive the Distribution. 

9.8 Waivers of Default. A waiver by a party of any default by the other party of any provision of this Agreement
shall not be deemed a waiver by the waiving party of any subsequent or other default, nor shall it prejudice the rights of the waiving party. No failure or delay by a party in exercising any right, power or privilege under this Agreement shall
operate as a waiver thereof, nor shall a single or partial exercise thereof prejudice any other or further exercise thereof or the exercise of any other right, power or privilege. No waiver by any party of any provision of this Agreement shall be
effective unless explicitly set forth in writing and executed by the party so waiving. 
 9.9 Force Majeure. No
party (or any Person acting on its behalf) shall have any liability or responsibility for failure to fulfill any obligation (other than a payment obligation) under this Agreement so long as and to the extent to which the fulfillment of such
obligation is prevented, frustrated, hindered or delayed as a consequence of circumstances of Force Majeure. A party claiming the benefit of this provision shall, as soon as reasonably practicable after the occurrence of any such event,
(a) notify the other parties of the nature and extent of any such Force Majeure condition and (b) use due diligence to remove any such causes and resume performance under this Agreement as soon as feasible. 

9.10 Notices. All notices, requests, claims, demands and other communications under this Agreement shall be in
writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by overnight courier service, by facsimile or electronic transmission with receipt confirmed (followed by delivery of an
original via overnight courier service) or by registered or certified mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given
in accordance with this section): 

  
 18 

 If to JDSU, to: 

JDS Uniphase Corporation 
 430
North McCarthy Blvd 
 Milpitas, California, USA 

95035 
 Attention: General
Counsel 
 Email: [—] 

with a copy to: 
 DLA Piper LLP
(US) 
 2000 University Avenue 

East Palo Alto, California 94303-2215 

Attention: Ed Batts 
 Facsimile:
[—] 
 Email: [—] 

If to Holdings or any Holdings Affiliate, to: 

Lumentum Holdings Inc. 
 400
North McCarthy Blvd 
 Milpitas, California USA 

95035 
 Attention: General
Counsel 
 Email: [•] 

with a copy to: 
 DLA Piper LLP
(US) 
 2000 University Avenue 

East Palo Alto, California 94303-2215 

Attention: Ed Batts 
 Facsimile:
[—] 
 Email: [—] 

9.11 Termination. Notwithstanding any provision to the contrary, this Agreement may be terminated and the Distribution
abandoned at any time prior to the Distribution Effective Time by and in the sole discretion of JDSU without the prior approval of any Person, including Holdings. In the event of such termination, this Agreement shall become void and no party, or
any of its officers and directors shall have any liability to any Person by reason of this Agreement. After the Distribution Effective Time, this Agreement may not be terminated except by an agreement in writing signed by each of the parties. 

  
 19 

 9.12 Changes in Law. 

(a) Any reference to a provision of the Code or a law of another jurisdiction shall include a reference to any applicable
successor provision or law. 
 (b) If, due to any change in applicable law or regulations or their interpretation by any court
of law or other governing body having jurisdiction subsequent to the date of this Agreement, performance of any provision of this Agreement or any transaction contemplated thereby shall become impracticable or impossible, the parties hereto shall
use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such provision. 

9.13 Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being
enforced under any Law or as a matter of public policy, all other conditions and provisions of this Agreement shall remain in full force and effect. Upon such determination that any term or other provision is invalid, illegal or incapable of being
enforced, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated by this Agreement be
consummated as originally contemplated to the greatest extent possible. 
 9.14 Entire Agreement. Except as otherwise
expressly provided in this Agreement, this Agreement constitutes the entire agreement of the parties with respect to the subject matter of this Agreement and supersedes all prior agreements and undertakings, both written and oral, between or on
behalf of the parties with respect to the subject matter of this Agreement. 
 9.15 Assignment; No Third-Party
Beneficiaries. This Agreement shall not be assigned by any party without the prior written consent of the other party, except that a party may assign any or all of its rights and obligations under this Agreement in connection with a sale or
disposition of any assets or entities or lines of business of such party or in connection with a merger transaction in which such party is not the surviving entity; provided, however, that, in each case, no such assignment shall
release such party from any liability or obligation under this Agreement nor change any of the steps in this Agreement, and the surviving entity of any merger or the transferee of such assets or businesses shall agree in writing to be bound by the
terms of this Agreement as if named as a party hereto. The provisions of this Agreement and the obligations and rights under this Agreement shall be binding upon, inure to the benefit of and be enforceable by (and against) the parties and their
respective successors and permitted transferees and assigns. This Agreement is for the sole benefit of the parties to this Agreement and their permitted successors and assigns, and nothing in this Agreement, express or implied, is intended to or
shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. 

9.16 Specific Performance. In the event of any actual or threatened default in, or breach of, any of the terms,
conditions and provisions of this Agreement, the party or parties who are or are to be thereby aggrieved shall have the right to specific performance and injunctive or other equitable relief (on an interim or permanent basis) of its rights under
this Agreement, in addition to any and all other rights and remedies at law or in equity, and all such rights and remedies shall be cumulative. The parties agree that the remedies at law for any breach or threatened breach, including monetary
damages, may be inadequate compensation for any loss and that any defense in any action for specific performance that a remedy at law would be adequate is waived. Any requirements for the securing or posting of any bond with such remedy are waived
by each of the parties. 
 9.17 Amendment. No provision of this Agreement may be amended or modified except by a
written instrument signed by each of the parties to this Agreement. No waiver by any party of any provision of this Agreement shall be effective unless explicitly set forth in writing and executed by the

  
 20 

 
party so waiving. The waiver by any party of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any other subsequent breach. The failure of any party to
require strict performance by any other party of any provision in this Agreement will not waive or diminish that party’s right to demand strict performance thereafter of that or any other provision of this Agreement. 

9.18 Rules of Construction. Interpretation of this Agreement shall be governed by the following rules of construction:
(a) words in the singular shall be held to include the plural and vice versa, and words of one gender shall be held to include the other gender as the context requires, (b) references to the terms “Article,” “Section,”
“paragraph,” “clause,” “Exhibit” and “Schedule” are references to the Articles, Sections, paragraphs, clauses, Exhibits and Schedules of this Agreement unless otherwise specified, (c) the terms
“hereof,” “herein,” “hereby,” “hereto,” and derivative or similar words refer to this entire Agreement, including the Schedules and Exhibits hereto, (d) references to “$” shall mean U.S.
dollars, (e) the word “including” and words of similar import when used in this Agreement shall mean “including without limitation,” unless otherwise specified, (f) the word “or” shall not be exclusive,
(g) references to “written” or “in writing” include in electronic form, (h) unless the context requires otherwise, references to “party” shall mean JDSU or Holdings, as appropriate, and references to
“parties” shall mean JDSU and Holdings, (i) provisions shall apply, when appropriate, to successive events and transactions, (j) the table of contents and headings contained in this Agreement are for reference purposes only and
shall not affect in any way the meaning or interpretation of this Agreement, (k) JDSU and Holdings have each participated in the negotiation and drafting of this Agreement and if an ambiguity or question of interpretation should arise, this
Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or burdening either party by virtue of the authorship of any of the provisions in this Agreement or any interim drafts of
this Agreement, and (l) a reference to any Person includes such Person’s successors and permitted assigns. 
 9.19
Counterparts. This Agreement may be executed in one (1) or more counterparts, and by each party in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute
one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or .pdf shall be as effective as delivery of a manually executed counterpart of this Agreement. 

  
 21 

 IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be executed by a duly
authorized officer as of the date first above written. 
  

	
	 JDS UNIPHASE CORPORATION

ON BEHALF OF ITSELF AND EACH
OF THE
 JDSU AFFILIATES

	
	 
	 By:
 Its:

 

	 LUMENTUM HOLDINGS INC.

ON BEHALF OF ITSELF AND EACH
OF THE
 HOLDINGS AFFILIATES

	
	 
	 By:
 Its:

  
  
  

SIGNATURE PAGE TO TAX MATTERS AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]